The effects of smoking cessation intervention in patients with coronary heart disease : a randomised, controlled trial by Quist-Paulsen, Petter
 
The effects of smoking cessation 
intervention in patients with coronary 
heart disease 
- a randomised, controlled trial 
Petter Quist-Paulsen 
 
 
 
 
 
 
 
 
Dissertation for the degree philosophiae doctor (PhD)  
at the University of Bergen 
 
 
 
 
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISBN 82-308-0285-8 
Bergen, Norway 2007 
 3 
Acknowledgements 
A large number of persons have made this thesis possible. I especially wish to thank: 
• Frode Gallefoss, MD, PhD, Department of Pulmonary Medicine, Sørlandet 
Sykehus Kristiansand and Professor at Institute of Internal Medicine, University 
of Bergen, my supervisor, for coming up with the idea, for the excellent team-
work we have had throughout these years, and for his  knowledgeable guidance, 
sound criticism, creativity, and never-failing enthusiasm. 
• Tone Bæck (project nurse), Department of Cardiology, Sørlandet Hospital 
Kristiansand for superbly delivering the intervention and solidly collecting the 
data, and for her smooth co-operation, enthusiasm and positive attitude when 
planning and conducting the study. 
• Eva Borøy (project nurse), Department of Cardiology, Sørlandet Hospital 
Kristiansand for superbly delivering the intervention and solidly collecting the 
data. 
• Anne Kari Kjellesvik (project nurse), Department of Cardiology, Sørlandet 
Hospital Kristiansand for superbly delivering the intervention and solidly 
collecting the data. 
• The nurses and the physicians at the Department of Cardiology, Sørlandet 
Sykehus Kristiansand for their thorough participant registrations, and patience 
during the trial. 
• Kjetil Drangsholt, MD, Vest-Agder Council for Public Health for his leadership 
of the steering committee, and planning of the study. 
• Pål Friis, MD, Superintendent Department of Medicine, Sørlandet Sykehus HF for 
planning the study and positivism as superintendent for the Medical Department 
during the trial. 
• Finn Tore Gjestvang, MD, Department of Cardiology, Sørlandet Sykehus 
Kristiansand for planning the study. 
• Anders Wahlstedt, former Director of Sørlandet Hospital Kristiansand for 
planning the study. 
• Professor Per Sigvald Bakke, MD, PhD, Institute of Internal Medicine, University 
of Bergen, my co-supervisor, for his help in writing paper II-IV, and expertise 
regarding the statistics. 
• Stian Lydersen, PhD. Professor in medical statistics, Unit for Applied Clinical 
Research, NTNU, Trondheim, for extrapolating the survival curves in paper IV.  
 4 
• Vest-Agder Council for Public Health, the charity “Sykehuset i våre hender”, and 
the Department of Science, Sørlandet Sykehus Kristiansand for funding the 
project.  
• Svein Gunnar Gundersen, MD, PhD and Sissel Ledang, Department of Science, 
Sørlandet Sykehus Kristiansand for their positive attitude during the writing 
process. 
• My wife Siri Ann for her love, support and encouragement. 
 
Trondheim, April 2006. 
Petter Quist-Paulsen.  
 
 
 5 
Introduction 
The local story before starting the study 
Frode Gallefoss MD, PhD, who is now the Superintendent of the Department of 
Pulmonology at Sørlandet Hospital Kristiansand, had for a long time been interested 
in helping patients with chronic obstructive pulmonary disease (COPD) and asthma 
to stop smoking, and he had also been working with the prevention of tobacco in the 
general population. As a doctor of internal medicine he had been worried about the 
lack of interest in smoking cessation among doctors treating patients with coronary 
heart disease, and he wondered why there were so little scientific papers on this topic. 
He did some power calculations, and found that a randomised trial on the effect of a 
smoking cessation program in these patients were possible to perform at our hospital. 
He gathered a steering committee, including the clever nurse Tone Bæck who later 
was to do most of the intervention and data collections. Frode had no time himself to 
carry the project as he was in the middle of his own PhD project about the effects of 
patient education in asthma and COPD. Therefore, I was asked to be the leader of the 
project. At that time I was working as an internist, and did not have scientific 
ambitions. But after reading the provisional description of the project I was 
astonished about the importance of the trial, and agreed to lead the project. Money 
was raised through an important donation from the Vest-Agder Council for Public 
Health. In the autumn of 1998, I sat down to write the protocol. Thanks to the 
recommendations from Frode this was done thoroughly, and most of the scientific 
questions discussed in this thesis have been prespecified in the protocol. I did not 
have ambitions regarding a PhD, but we were convinced that the quality of the 
project should be at a “PhD-level”. During this stage the steering committee had 
several meetings, and together I believe we managed to create a sound protocol. After 
the start of the study in the beginning of 1999 all were up to the study nurses, who we 
knew were clever in their work, and who we thought were able to deliver the 
intervention as intended. The rest of the story may demonstrate the impact of 
multidisciplinary co-operation in medicine.  
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Abstract 
Background 
Smoking cessation is the most important action to reduce mortality after a coronary 
event. Largely, it has previously been unknown whether a smoking cessation 
program applicable in an ordinary clinical setting has any impact on smoking 
cessation rates in patients with coronary heart disease, and whether such a program is 
cost effective. 
Objectives 
To determine whether a nurse managed smoking cessation intervention changes 
abstinence rates in patients admitted for coronary heart disease, to assess the 
predictors of smoking cessation, to evaluate whether smoking cessation has any 
impact on Quality of Life, to estimate the cost effectiveness of the smoking cessation 
program, and to appraise the feasibility of a fear arousal message. 
Design 
Randomised controlled trial of usual care compared with individual smoking 
cessation intervention. 
Setting 
The cardiac ward in Sørlandet Sykehus, Kristiansand, Norway. 
Participants 
240 smokers under 76 years of age admitted for myocardial infarction, unstable 
angina or cardiac bypass surgery. 118 were randomly assigned to the intervention and 
122 to usual care (control group). 218 patients (91%) completed the study and were 
assessable at 12 months follow up. 
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Methods 
The intervention was based on an especially made 17 page booklet and focused on 
fear arousal and relapse prevention. Individual smoking cessation was delivered by 
cardiac nurses without special training. The intervention was initiated in hospital, and 
the participants were telephoned regularly for at least five months. Abstinence rates 
were determined by self report and biochemical verification.  
Survival data from previously published investigations, with life time 
extrapolation of the survival curves by survival function modelling, were used to be 
able to estimate the cost effectiveness of the program.  
Baseline characteristics were prospectively recorded, and health-related Quality of 
Life was measured at baseline and at 12 months follow up. The patient satisfaction 
was assessed at 12 months follow up. 
Results 
12 months after randomisation 57.0% and 37.3% were abstinent in the intervention 
and control groups, respectively (95% confidence interval for the difference 6.4 to 
33.0). The number needed to treat  to get one additional quitter was 5.1 (95% CI 3.0 
to 15.6). Assuming all drop outs returned to smoking at 12 months, the cessation rates 
were 50.0% and 37.0%  in the intervention and control group, respectively (95% CI 
for the difference 0.4 to 25.7).  
In a life time perspective, the incremental cost per year of life gained by the 
cessation program was Euro 280 and Euro 110 in the low and high risk group, 
respectively (2000 prices). These costs compare favourably to other treatment 
modalities in patients with coronary heart disease, being approximately 1/25 the cost 
of both statins in the low risk group and angiotensin converting enzyme inhibitors in 
the high risk group. In a sensitivity analysis, the costs remained low in a wide range 
of assumptions. 
The participants were in general satisfied with the cessation program, 
indicating that implementing a fear arousal message is a feasible method. 
In multivariate logistic regression analysis, a high level of nicotine addiction 
was a strong negative predictor of smoking cessation in both the intervention and the 
control group. 
The quitters and sustained smokers had similar improvements in all Quality of 
Life domains from baseline to 12 months follow up. Further, after adjustment for 
differences in baseline characteristics, the Quality of Life at baseline was not 
significantly associated with smoking cessation at 12 months follow up.   
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Conclusions 
A smoking cessation program delivered by cardiac nurses without special training, 
significantly reduced smoking rates 12 months after hospitalisation for coronary heart 
disease. The program was very cost effective compared to other treatment modalities 
in patients with coronary heart disease in terms of cost per life year gained. Among 
those with a high level of nicotine addiction, more effective cessation programs are 
needed.  
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Background 
The history on Tobacco (1) 
The origin of the tobacco plants are from America, and they have been used for 
millenniums by the Indians. Tobacco was introduced to Europeans with Columbus in 
1492, and by the late 1600s it was grown on every continent. The appeal of  nicotine 
in these plants quickly gained popularity. Traditionally the tobacco smoke was 
alkaline, where nicotine as a free base was readily absorbed by the oral mucosa (i.e. 
cigar smoke and snuff). In the mid-19th century the tobacco leaves were exposed to 
high temperatures, creating an acidic pH. This generated nicotine salts dissolved in 
droplets of smoke aerosol, and resulted in milder smoke which could be inhaled. The 
nicotine could thereby be absorbed by the respiratory epithelium. An ultimate 
addictive was created: A drug that gave a pleasant feeling with a very rapid increase 
in blood concentration after inhalation, reaching the brain within seconds. This 
discovery boosted the cigarette industry, and by the start of the 20th century famous 
companies like Camel and Lucky Strike spread cigarettes throughout the world.  
 By the 1920s concerns about a link with lung cancer were growing among 
physicians, and in 1939 a Science report showed that smokers had a substantially 
higher mortality rate than non-smokers. During the 1950s evidence that smoking 
caused serious diseases rapidly developed. By the early 1990s it became evident that 
passive smoking also was dangerous, and tobacco smoke was regarded as a major 
pollution problem. Since then, tobacco giant Philip Morris of Marlboro has lost all 
appeals and will have to pay more than $82 million to the widow of a long-time 
smoker, many countries have abandoned smoking in public places, and people are 
beginning to call for a prohibition law.   
The prevalence of smoking  
Although smoking have been slowly declining in the western Europe and north 
America during the last thirty years, it increases rapidly throughout the developing 
world, and up to 70% of the population in several Asian countries are now daily 
smokers. In the United States, approximately 20% are smoking (2), and in Norway 
25% are daily smokers between 16 and 74 years of age (3). A further 11% are 
occasional smokers (3). Especially in western Europe and north America smoking is 
now most prevalent among people with a low level of education,. In Norway there 
are three times as many smokers in this group than in those with a high level of 
education (3). 
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The health problems of smoking 
World-wide, approximately 5 million people die each year because of smoking (2, 4). 
Tobacco is regarded as the greatest preventable cause of death (4), and is one of the 
biggest threats to the world health (4). On average, lifelong smoking shortens the life 
expectancy with about 10 years (5), and it has been estimated that smoking one 
cigarette on average reduces life expectancy with 11 minutes (6). A survey of British 
male doctors showed that the chance of reaching 73 years of age in life long smokers 
were 42% compared to 78% in life long non-smokers (7). Pulmonary and 
cardiovascular diseases are the most frequent causes of death in smokers, causing  
approximately 50% and 35% of smoking related deaths, respectively (2, 4).  
Smoking as a risk factor for coronary heart disease 
Many observational studies have shown that smoking is an important risk factor for 
the development of coronary heart disease (8-11). Compared with non-smokers, 
current smokers have a two- to four-fold higher risk of coronary heart disease and 
sudden death (9-11). Even as few as one to four cigarettes per day increase the risk of 
myocardial infarction (12), and smokers are on average ten years younger than non-
smokers when they develop myocardial infarction (13).  
 The tobacco smoke is composed of over 4000 components. The pathogenic 
mechanisms explaining why these components increase the risk of coronary heart 
disease are not fully understood. Nicotine itself does not seem to increase the risk 
significantly (14). Experiments have shown the following effects of cigarette 
smoking, all of which could contribute to coronary heart disease: 
• Impaired endothelial function (15), which may be the cause of the increased 
atherosclerosis found in smokers (8). 
• Vastly increased platelet activity, which arises acutely after smoking one cigarette 
(16). 
• Acutely increased vascular resistance with decreased coronary flow velocity (17). 
• Acutely vasospasm, including vasospastic angina (18). 
The increased risk associated with smoking declines rapidly after cessation, 
and after two years of abstinence the relative risk nearly equals the risk of non-
smokers (19), suggesting that factors other than atherosclerosis per se are involved in 
the pathogenesis.   
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Why is it important that patients with coronary heart 
disease quit smoking? 
Smoking cessation after a myocardial infarction or unstable angina is associated with 
an approximately 50% relative mortality reduction after five years compared to 
sustained smoking (20, 21). With a longer follow up period, this reduction increases 
further, as shown by this figure adopted from Daly et. al. (22): 
 
Thirteen years after myocardial infarction or unstable angina only 18% were still 
alive among those who continued to smoke, compared to 63% among the quitters.  
It is both unethical and impossible to randomise patients to continued smoking 
or smoking abstinence after a coronary event. Therefore, we are left with 
observational data which is often misleading. Smokers with an acute coronary event 
tend to be younger and with fewer concomitant cardiac risk factors than non-smokers 
(13). Therefore, their initial prognosis have been shown to be more favourable than 
non-smokers (“smokers paradox”) (13). Thus, significant differences in mortality 
between quitters and persistent smokers may take several years to develop. Further, 
most investigations have not verified quitters biochemically despite the fact that as 
many as 10-30% do not tell the truth about their smoking behaviour (23), and that 
many return to smoking within a year (24). All these biases tend to underestimate the 
effect of smoking cessation. Hence, the benefit of quitting smoking after a coronary 
event might be even greater than reported. 
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1
0 2 4 6 8 10 12 14
Years after myocardial infarction or unstable angina
Pr
op
or
tio
n 
su
rv
iv
in
g
Quitters
Sustained smokers
 16 
Why is it so difficult to quit smoking?   
Each year about one third of the smokers try to quit, but only approximately 3% of 
the quit attempts result in sustained (12 months) cessation (25). Ten seconds after 
inhalation very high level of nicotine reaches the brain, and stimulates the nicotine 
acetylcholine receptors (25). In response, dopamine is released which speeds reaction 
times, and improves attention, concentration and problem-solving  (14, 25). However, 
this system adapts after a few hours, and becomes downregulated (14, 25). But after a 
night sleep the system partly upregulates, and the first cigarette in the morning 
produces arousal and relaxation. Most regular smokers experience withdrawal 
symptoms some hours after the last cigarette: Irritability, restlessness, feeling 
miserable, and impaired concentration (25). These symptoms affect behaviour and are 
a strong impetus to start smoking again, as all symptoms vanish immediately after 
inhalation of a cigarette (14, 25). Thus, the withdrawal symptoms are an important 
cause of the addiction (14, 25).   
Population strategies to prevent smoking 
The most effective way to reduce the prevalence of smoking is public intervention 
(26). Evidence exists for the efficacy of the following initiatives: Abandoning 
smoking in public places and work places, prohibiting tobacco advertisement, 
educating people about the health hazards of smoking, providing cessation 
clinics/telephone counseling, and increasing the prices of the tobacco products (26).   
What kind of smoking cessation modalities are effective 
among the general population? 
In people without a special incitement for cessation, the sustained quit rates are rather 
low (i.e. 5%-10%), regardless of the type of intervention. However, several treatment 
modalities have proven their efficacy: Individual behavioural counseling (27), group 
behavioural therapy (28), telephone counselling (29), and self-help materials (i.e. 
booklet, video) (30). Regarding pharmaceutical products, nicotine replacement 
therapy has been shown to almost double the cessation rates (31), and bupropion 
might be of similar efficacy (32). 
A stage based transtheoretical model has been widely recommended in 
smoking cessation (33). This model separates individuals into five different stages 
(precontemplation, contemplation, preparation, action, and maintenance), and 
different interventions are used in each stadium. Accurate investigation and treatment 
have to be applied as the individuals progressively go through the different stages 
(33). This process is rather complicated, and often needs psychologically trained 
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personnel. Why this method has gained so much popularity is difficult to understand 
as a systematic review did not find evidence for its efficacy (34). Simple 
interventions can probably suffice, and not even thorough planning seems necessary 
as most successful quit attempts may be unplanned (35)! 
What kind of smoking cessation modalities are effective 
among hospitalised patients? 
Among hospitalised patients, several trials have shown that intensive intervention 
started at hospital plus follow-up for at least one month significantly increases quit 
rates (36). Adding nicotine replacements seem to increase the quit rates further (36), 
and applying both methods can double the cessation rates compared to usual care 
(36). Brief interventions during hospitalisation have not shown significant effect (36, 
37). The kind of provider does not seem to matter, as smoking cessation intervention 
delivered by psychologists, physicians, and nurses are all of similar efficacy (38). 
Investigations on smoking cessation intervention in patients 
with coronary heart disease 
Randomised investigations on smoking cessation methods in patients with coronary 
heart disease have obtained mixed results. Several studies of interventions to change 
lifestyle, where smoking cessation was only part of the intervention, have been 
performed (39-45). Most of them did not show any significant effect on quit rates 
(39-42).  
Regarding studies only addressing smoking cessation, brief interventions 
during hospitalisation  have been ineffective (46-48). Such brief interventions usually 
include a firm advice from a physician to stop smoking, information about the health 
hazards of continued smoking, and self help materials. It is this kind of smoking 
cessation intervention that is recommended from the Joint European Societies, which 
includes the European Society of Cardiology (49). It is also the most widely used 
method to increase quit rates among coronary heart patients (49). Therefore, it is very 
disappointing that this method does not seem to be of any significant effect (46-48). 
In a recent paper (49), and in a companion news report in the BMJ (50), more 
efficient ways to improve quit-rates were asked for.  
Before the start of our project, three randomised trials had investigated 
whether a smoking cessation program with several months of intervention was able to 
increase the quit rates (51-53). The first was a Lancet paper showing  62% abstainers 
in the intervention group compared to 28% in the usual care group (51). The 
intervention principles were rather simple: Patients in the intervention group were 
told that continued smoking could lead to further heart attacks because it would 
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narrow the arteries in a manner similar to furring in a pipe, sometimes with complete 
blockage. Some information on how to quit were sometimes given. The article does 
not describe the length of the intervention, and unfortunately no biochemically 
verification of the quitters were performed. Another investigation in patients after 
coronary arteriography randomised patients to a behavioural smoking cessation 
program with a mean of four telephone calls during four months, or usual care (52). 
After 12 months there was a trend toward increased quit-rates in the intervention 
group, but not reaching standard level of statistical significance (57% versus 48% 
cessation rates in the intervention and the usual care group, respectively, p0.06). 
However, the intervention seemed effective in the subgroup with more severe 
disease. A third study showed a 71% cessation rate in the intervention group 
compared to 45% in the usual care group one year after admission for myocardial 
infarction (53). The intervention was delivered by especially trained nurses using 
social learning theory combined with addiction models. The patients were followed 
regularly for 4 months. The main drawback of this study was the application of a 
rather complicated psychological approach, which  may be difficult to implement in 
clinical practice. After our trial was started in 1999, one more investigation has been 
published. Dornelas et. al. randomised 100 patients after myocardial infarction (54). 
The intervention was delivered by a psychologist implementing the transtheoretical 
model, and consisted of bedside counselling followed by regular telephone calls 
during 6 months. After 12 months 34% and 55% were abstinent in the usual care 
group and intervention group, respectively (p<0.05). The use of the complicated 
transtheoretical model may be unnecessary in cardiac patients, because most patients 
suffering an acute coronary event stop smoking while hospitalised (53, paper I). 
Therefore, they already are in the last stadium of the transtheoretical model (the 
maintenance stage), and focusing only on relapse prevention seems more logical. 
Further, the study had a low number of patients, and lack of biochemical verification 
of the quitters. 
Regarding pharmaceuticals, there are no studies with a long-time follow up 
period only investigating the effects of nicotine replacements in patients with 
coronary heart disease (36). On the other hand, they have been incorporated in many 
of the studies mentioned above (41, 43, 46, 48, 53), and  have been found to be safe 
(55). In a Cochrane review, the authors concluded that nicotine replacements 
probably increase quit rates if combined with high intensity behavioural intervention 
(36). Since the start of our project, bupropion has gained popularity. This 
psychopharmaceutical product has been shown to be safe and effective in patients 
with coronary heart disease, with a continuos cessation rate of 22% in the bupropion 
group compared to 9% in the placebo group at 12 months follow up (p<0.01) (56). 
However, its effect in combination with behavioural therapy in patients with heart 
disease is still unknown.  
In conclusion, smoking cessation interventions given briefly during 
hospitalisation or given as part of a life style intervention program are ineffective 
regarding quit rates. At start of our study there were some evidence that an individual 
smoking cessation intervention with  several months of follow up had significant 
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effect, and that such therapy should be combined with nicotine replacements. 
However, it was unknown whether such a program could be delivered by personnel 
without special education in smoking cessation, and whether simple intervention 
principles applicable in an ordinary clinical setting, could be used.   
Who manage to quit smoking after a coronary event?  
Several investigations have assessed the predictors of smoking cessation in patients 
with coronary heart disease (46, 53, 54, 58, 60-62). The results have been mixed, but 
the following predictors have rather consistently been found to be positively 
associated with smoking cessation:  
• Low level of nicotine addiction (46) (most often as assessed by the Fagerstrom 
index (57)). 
• High level of self confidence in smoking cessation (53, 54, 58) (as assessed by the 
total self efficacy score (59)).  
• The severity of the coronary event, i.e. having myocardial infarction as reason for 
admission (46, 60, 61).  
• Having no previous heart disease (62). 
• Low level of hostility and depression (60).  
Whether a smoking cessation program has any impact on these predictors has 
not previously been evaluated. A better characterisation of how these predictors are 
affected in a smoking cessation program may help to improve the intervention, and 
this was the ambiguous aim for paper II.  
Does smoking cessation has any impact on Quality of Life? 
As mentioned previously, quitting smoking is the most effective single action to 
reduce mortality after a coronary event. However, improvement in Quality of Life 
(QoL) may be equally important (63). Despite some authors claim that smoking 
cessation improves QoL (2), there are no evidence that this is true. Surprisingly few 
studies have assessed this question. In the general population, two studies have 
obtained mixed results (64, 65). In patients with coronary heart disease only one 
investigation has been performed on this topic (66), and this found that patients who 
managed to give up smoking after percutaneous coronary intervention improved their 
health-related QoL to a greater extent than sustained smokers. However, this study 
included patients without motivation to stop smoking and adequate adjustments for 
confounders may have been difficult to perform.  
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Thus, whether smoking cessation in patients with coronary heart disease has 
impact on QoL is largely unknown. Further, whether QoL life is a predictor of 
smoking cessation has never been analysed. These questions were the aims of paper 
III. 
Is a smoking cessation program in patients with coronary 
heart disease cost effective? 
After the main result of our trial was published, in our opinion there were no longer 
doubt that a smoking cessation program with several months of intervention 
significantly increased smoking cessation rates. Despite this, most hospitals do not 
provide such programs as part of routine care (49), possibly because they are thought 
not to be worth their costs. As the therapeutic arena becomes more crowded, and in 
times of health economic constraints, analyses of treatment costs relative to 
healthcare benefits are important. Cost effectiveness analyses in terms of cost per 
year of life saved or gained provide this opportunity, enabling us to compare the 
various treatment modalities (67). Several cost effectiveness analyses have been 
published on secondary prevention strategies for cardiovascular disease (68). 
Regarding smoking cessation intervention, only one study has been performed (69). 
This 13 year old analysis was based on a study of patients suffering myocardial 
infarction in the sixties (70), and showed that a smoking cessation program was cost 
effective compared to other treatment modalities. Whether similar smoking cessation 
programs after coronary revascularisation or unstable angina also are cost effective 
have previously been unknown. If a favourable cost effectiveness ratio of our 
cessation program could be demonstrated, this would serve as an argument for a 
wider implementation of similar programs. 
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Objectives 
The main objectives of the present study in patients admitted for coronary heart 
disease were: 
• To examine the effect of a smoking cessation program on the smoking cessation 
rates at 12 months follow-up (paper I). 
• To assess the predictors of smoking cessation, and examine whether these could 
be influenced by a smoking cessation program (paper II). 
• To evaluate whether smoking cessation improves health related QoL in a one year 
perspective (paper III). 
• To perform a cost effectiveness analysis of the smoking cessation program (paper 
IV). 
• To examine the patient satisfaction of a smoking cessation program based on a 
fear arousal message (paper V). 
 22 
Materials and methods 
Participants 
All patients admitted to Sørlandet Hospital, Kristiansand for myocardial infarction, 
unstable angina or postoperative care after coronary bypass surgery were registered 
(bypass surgery was performed at hospitals in Oslo). Eligible patients had to be under 
76 years of age and daily smokers until the start of their present coronary symptoms. 
Patients with bypass surgery had to be daily smokers until they received the date of 
operation, and the cause of operation had to be symptomatic coronary artery disease. 
Patients had to be recovered enough to reliably receive the intervention, had to be 
able to read Norwegian, and had to live in Vest- or Aust-Agder county. Patients with 
the following conditions were excluded: Serious illnesses with short life expectancies 
(cancer, serious chronic obstructive lung disease, serious renal or liver failure), 
serious psychiatric problems, alcoholism and dementia.   
The study was approved by the regional ethics committee, and permission to 
establish a register of the participants was given by the National Data Supervision 
Centre (“Data-tilsynet”).  
Sample size 
We aimed to detect a 20% difference between the two groups. With a power of 80% 
(β=0.2) and α<0.05, 98 patients were needed in each group (χ2 , two tailed test, 
Sample Power version 1, SPSS Inc., Chicago). To allow for drop outs, an enrolment 
of 250 patients was decided. From the patient administration system in DIPS, the 
numbers of relevant patients available in 1997 were found. We assumed that 50% of 
available patients were smoking, that 15 % did not want to participate, and that 15% 
were not fulfilling the inclusion criteria. Thereby, an inclusion period of 2-2.5 years 
were estimated.  
Randomisation  
The study nurses recruited patients two to four days after admission. After signing a 
written informed consent and answering baseline questionnaires (appendix III-VIII), 
participants were randomly allocated to the control (usual care) or the intervention 
group. The nurses were given a serially numbered sealed envelope from a secretary 
who was otherwise uninvolved in the study. The randomisation was in blocks with 
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varying sizes. The envelopes were made by an external part who also was otherwise 
uninvolved in the study.  
Intervention 
Physicians were not involved in the program. Our intention was that all participants 
in the control and intervention groups should receive the physicians’ ordinary quit-
smoking messages, and no other special attention from doctors regarding smoking 
cessation. During the trial the doctors were not informed of the patients’ inclusion or 
randomisation status.  
Control group 
All cardiac patients, independent of study participation, were offered group sessions 
conducted by cardiac nurses twice per week, in which the importance of  smoking 
cessation was mentioned. A video shown during these sessions and a booklet handed 
out to all patients contained general information on coronary heart disease, which 
included advice to give up smoking. Besides this, the control group received no 
specific instructions on how to stop smoking.  
Intervention group 
One of three cardiac nurses consulted the patients one or two times during the 
hospital stay. The intervention was based on a 17 page booklet especially made for 
the purpose of the trial (appendix XI). This manual emphasised the health benefits of 
quitting smoking after a coronary event. Two figures showed the mortality 
differences between those who continued smoking and those who stopped smoking 
after myocardial infarction or unstable angina. One of the figures was a bar chart 
showing 60% risk reduction for death after 5 years if quitting (71), and the other was 
a linear chart showing that after 13 years 18% of  continued smokers were alive 
compared to 63% of the quitters (22).  On the basis of these figures the participants 
were told that they most probably would suffer a new heart attack if they continued 
smoking, and that their risk of death would be markedly increased if they continued 
smoking  (fear arousal message). 
 The booklet also contained chapters on how to prevent relapse, how to stop 
smoking for those who either continued smoking or relapsed, and how to use nicotine 
replacements. How to identify and cope with high risk situations for relapse was 
explained, and action plans for coping with these situations were suggested. 
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The patients were strongly advised not to smoke during hospitalisation. Those 
with strong withdrawal urges were advised nicotine replacements (gum or patch). If  
spouses smoked, they also were asked to quit. 
The study nurses initiated telephone contacts two days, one week, three weeks, 
three months, and five months after hospital discharge. Those with special needs were 
telephoned monthly thereafter. At six weeks, at the day they were scheduled for the 
follow up appointment with a physician, all participants in the intervention group had 
a consultation with the study nurses at the outpatient clinic. The outpatient contacts 
included positive feedback (e.g. ”Congratulations, you are still free of smoking. That 
means that you already have a much lesser chance of suffering a new heart attack.”) 
and relapse prevention. The health benefits of quitting were repeated, and if 
necessary a fear arousal message was given. Those who either continued smoking or 
relapsed were offered additional support and advice.  
Apart from a one-day course in smoking cessation counselling, the study 
nursed had no special training in smoking cessation intervention.  
Outcome measures 
The participants were asked to return 12 months after inclusion for follow up 
assessment. Patients missing the appointment received a new letter. If they again 
missed the appointment, they were telephoned and asked to return to the hospital. If 
they still did not show up, a home visit was suggested.  
Paper I - The smoking cessation rates  
Patients who stated they were smoking at 12 months follow up were classified as 
smokers. Those who claimed to be quitters and had a urinary nicotine metabolite 
concentration < 2.0 mmol/ mol creatinine were classified as non-smokers (clinical 
decision limit as validated at Sahlgren’s University Hospital). Urinary nicotine 
metabolite analyses were performed at Sahlgren’s University Hospital, Sweden. The 
Diagnostic Product Corporation’s Nicotine Double Antibody Method with 125I 
radioimmunoassay was used, with cotinine as standard for calibration, and calibration 
values  0.6-85.5 umol/L.  
Paper II - The predictors of smoking cessation 
The study nurses prospectively recorded medical history and sociodemographic data 
(appendix III, IV). The participants filled in three questionnaires before 
randomisation, containing information on smoking habits (appendix V), nicotine 
addiction (the “Fagerstrom score”, appendix VI) and self-efficacy in smoking 
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cessation (the “Motivation and Relapse” form, appendix VII). Further details 
regarding these forms have been explained in paper II. The patients’ use of nicotine 
substitutions and their partners’ smoking status were registered at 12 months follow 
up.  
Paper III - The Quality of Life after smoking cessation 
Health related QoL was assessed before randomisation and at 12 months follow up. 
The questionnaire used in the Cardiac Arrhythmia Suppression Trial (CAST) was 
employed (72). This questionnaire contains a battery of established scales and items, 
to produce a specific health-related QoL instrument for patients with coronary heart 
disease. Six QoL dimensions were derived from 24 questions addressing the topics 
Social function, Physical function, Symptoms, Mental health, Life satisfaction, and 
Life expectancy (appendix V). The questionnaire has been designed to be especially 
sensitive to clinical changes in patients with coronary heart disease (73), and has been 
shown to be reliable, clinically valid, and sensitive to changes over time (73, 74). In 
an editorial comment the questionnaire was advocated for assessment of health-
related QoL in patients with coronary heart disease (75). For further detail regarding 
the QoL measurements, see paper III. 
Paper IV - The cost effectiveness of the smoking cessation 
program 
The incremental cost effectiveness of the program was assessed as the cost per life 
year gained, and was calculated using the following formula:  
(Cost of the program per patient x Number needed to treat to get one 
additional quitter (NNT)) / Gain in mean discounted life years per patient among 
quitters compared to sustained smokers. 
The variables in this formula were derived as follows: 
• The cost of the program was calculated on the basis of  Norwegian prices in 2000 
and were converted to Euro at the 2000 mean exchange rate (Euro 1=8.1 
Norwegian Krones, NOK). The nursing costs were estimated from the average 
salary of specialised nurses in Norway with more than ten years of seniority (190 
NOK/h). The printing costs of the self help material (17 NOK per booklet) were 
included. The office rental was set to 1500 NOK per square meter per year. The 
costs of telephoning were calculated using the prices of the telephone company 
Telenor (0.89 NOK per call + 0.49 NOK per minute). Because the expenses of the 
program only lasted for less than a year, discounting was not performed regarding 
the costs. Indirect costs (i.e. time lost from work while participating in the 
program) were not included in analysis because the intervention after discharge 
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from hospital were brief and mostly by phone. For further details regarding the 
estimation of the cost of the program, see paper IV. 
• The number needed to treat (NNT) to get one additional quitter from the smoking 
cessation program was derived from the absolute risk reduction (ARR) in 
smoking rates in the intervention group compared to the usual care group at 12 
months follow up (NNT= 100/ARR).  
• The gain in mean discounted life years per patient in quitters compared to 
sustained smokers were obtained from the differences in integrals between the 
survival curves of quitters and sustained smokers, and was assessed in a low- and 
high risk model. In the low risk setting survival data from van Domburg et. al. 
were used. They investigated 985 patients who underwent coronary bypass 
surgery during the seventies (76), and found an average annual mortality rate of 
1.7% at 10 years follow up. This rate of mortality rate was similar to the findings 
in the Scandinavian simvastatin survival study (4S) of patients with stable 
coronary artery disease (77). After a median follow up period of 20 years, the 
relative risk reduction in quitters compared to the sustained smokers was 28% 
(76), which is lower than in comparable investigations (21). The Kaplan Meier 
method was used for analysing the survival data for the first 20 years (76), and we 
extrapolated the survival curves further by using the Gompertz parametric 
survival function (78). 
Patients suffering myocardial infarction or unstable angina were chosen as the 
high risk group. There are no recent studies with a long follow up period and with 
proper verification of quitters, investigating the mortality benefit if quitting smoking 
in these patients. Therefore, a rather old investigation had to be chosen when 
calculating the survival differences in quitters and sustained smokers in a high risk 
setting (22).  However, the rate of mortality in this study was similar to the annual 
mortality rate of 4.5% found in a more recent survey of patients after thrombolysis 
for myocardial infarction (79). Survival curves were estimated for 13 years using life 
table methods (22), and were estimated in a life time perspective (i.e. 25 years) by 
assuming the survival thereafter followed an exponential function (the declining 
exponential approximation of life expectancy (80)).  
 The differences in integrals between the survival curves of quitters and 
sustained smokers were then calculated from year i to year i+1, multiplying that by 
1/1.05i  (5% discounting per year (67)) and summing for i = 1 to 40 in the low risk 
model and i = 1 to 25 in the high risk model. A short time perspective (five years) 
was also set up, summing for i = 1 to 5. 
See paper IV for further details regarding the estimation of the gain in life 
expectancies in quitters versus sustained smokers. 
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Paper V - The patient satisfaction 
At 12 months follow up the patient satisfaction was measured by the “Evaluation 
form” (appendix X), containing questions on the degree the participants felt they 
were helped by the hospital in quitting smoking and on the satisfaction of this help  
Statistical methods 
The χ2 test was used to assess the smoking cessation rates in the control group 
compared to the intervention group, and to assess other differences between the 
randomised groups when variables were categorical. The number needed to treat with 
confidence intervals, were calculated (81). Continuos variables were tested for 
normal or skewed distribution  by the Lilliefors’ test. The differences in means 
(continuos variables) between the randomised groups were assessed with the 
independent samples T tests and the Mann Whitney U-test for normally and 
nonnormally distributed data, respectively. 
Regarding the evaluation of differences in means (i.e. the QoL- and the patient 
satisfaction scores) between non-randomised groups (i.e. quitters versus sustained 
smokers), multivariate linear regression analyses were applied in order to be able to 
adjust for differences in baseline characteristics. 
When analysing differences within groups (i.e. the QoL improvements from 
admission to 12 months follow up) paired samples t-test and Wilcoxon test for two 
related samples were used for normally and nonnormally distributed data, 
respectively.  
Univariate and multivariate logistic regression models were used to test the 
relations between baseline characteristics (covariates/predictors) and the cotinine-
validated smoking cessation rates at 12 months (dependent variable). Variables 
showing significant correlation in univariate analyses were included in the 
multivariate tests. In the subgroup analyses, interaction terms were added to the 
logistic regression models to examine if the influence of the covariates on the 
dependent variables were significantly different in the control group compared to the 
intervention group (subgroup interaction analysis).  
All tests were two-tailed with 0.05 significance level (alpha) and 95% 
confidence interval. We used SPSS for Windows (version 11 and 12) for all analyses. 
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Results 
Paper I - The smoking cessation rates 
Patients were recruited from February 1999 to September 2001. The following figure 
shows the participant flow through the trial: 
 
* Sixty-two patients were older than 75 years, four did not live in a nearby community, five did not read    Norwegian, 
seven had dementia, nine had psychiatric problems, nine had other serious illnesses and eight were alcoholics.   
** Seven died before randomisation, one had no telephone, and two were registered too late. 
*** All had normal coronary angiograms.  
† All received the allocated intervention 
 
Figure 1. Participant flow
766 excluded:
595 did not smoke
104 not meeting inclusion criteria*
57 refused to participate, 10 had other reasons**
10 patients (seven allocated to intervention and
three alloctated to control) were withdrawn
because their diagnosis were later refuted***
100 analysed †
18 were lost to follow up:
Fourteen withdrew
Three died
One changed adress
118 allocated to the intervention group
118 analysed.
Four were lost to follow up:
One withdrew
Two died
One changed adress
122 allocated to the control group
250 randomised
1016 assessed for eligibility
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Most patients (85%) received more telephone calls than the intended minimum 
of five. The mean total time devoted to each patient was approximately 2.5 hours, 
including time to fill in questionnaires for the purpose of the trial. A third of the 
participants used nicotine replacements. 
At 12 months follow up, the intervention group had a statistically significant 
20% increased cessation rate compared to the control group (NNT 5). Due to a higher 
drop out rate in the intervention group, in an intention to treat analysis the difference 
in quit rates between the groups was 13% (NNT 8, still statistically significant).  
The groups showed similar smoking cessation rates while in hospital and at six 
weeks’ follow up.  
Paper II - The predictors of smoking cessation 
When analysing the control and intervention groups combined, a high level of 
nicotine addiction, a low level of self confidence in quitting, and having previous 
coronary heart disease all were significant negative predictors of smoking cessation 
in a multivariate analysis. We speculate whether our smoking cessation program was 
especially important among patients with no previous coronary heart disease and 
another diagnosis than myocardial infarction, although the differences between 
groups did not reach level of significance in subgroup interaction analyses.  A high 
level of nicotine addiction was the strongest negative predictor in both groups. Our 
results indicate that the level of nicotine addiction  can be assessed with one simple 
question; are you smoking the first cigarette in the morning within 30 min of waking? 
This is easier than applying the Fagerstrom Questionnaire which covers eight items 
of various aspects of smoking behaviour. 
Paper III - The Quality of Life after smoking cessation 
Even when applying a questionnaire especially designed to be sensitive for changes 
in patients with coronary heart disease, we did not find that the health-related QoL 
improved with smoking cessation in a one year perspective. Further, the QoL was not 
a significant predictor of smoking cessation. 
Paper IV - The cost effectiveness of the smoking cessation 
program    
Due to the vast uncertainties associated with cost effectiveness analyses we aimed to 
do conservative assumptions, thereby calculating a maximum cost per life year 
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gained by the program. The only important cost of the program was the 2.5 hours of a 
nurse’s working time. This one time investment gave a much lower cost effectiveness 
ratio than pharmaceuticals which have to be taken every day for years (i.e. 1/25 the 
cost of both statins in the low risk group and angiotensin converting enzyme 
inhibitors in the high risk group).    
Paper V - The patient satisfaction 
Compared to the control group, participants in the intervention group stated they had 
got significantly more information on the tobacco’s effect on the heart, that the 
hospital had helped them significantly more in quitting smoking, and that they were 
significantly more satisfied with the help they had got from the hospital in quitting 
smoking (question 2, 5 and 6 from the “Evaluation form”, appendix X). On a scale 
from 1 (very unsatisfied) to 5 (very satisfied), the participants in the intervention and 
control group had a mean score of 4.1 and 2.9, respectively, on these three questions. 
These differences were not due to increased cessation rates in the intervention group, 
as both sustained smokers and quitters scored significantly higher in the intervention 
group than in the control group on all the three questions. 
   
 31
Discussion 
Methodological considerations 
The study design and the smoking cessation rates 
A randomised controlled trial (RCT) is the gold standard in evidenced based 
medicine (82, 83), but does encompass some problems. Many RCTs only include a 
highly selected group of patients, thereby making the results difficult to implement in 
daily practice. We wanted to create a study which was applicable and feasible in an 
ordinary clinical setting. Therefore, we had to include most smoking patients with 
coronary heart disease, and the intervention principles had to be simple. Of eligible 
patients, 19% (n=57) refused to participate. Most of these patients did not want to 
quit smoking. A wish to stop smoking was a prerequisite for inclusion in the trial. 
The applicability of our results could have been further strengthened by also inviting 
these patients to participate. On the other hand, working with participants not 
motivated to quit smoking is most probably ineffective, and might have been 
demoralising for the study nurses.  
Ideally a RCT should be double blinded (83), but due to the type of 
intervention blinding was not possible in our trial. We tried to compensate for this 
potential bias by not telling the participants in which group they were allocated. Still, 
the intervention group may have regarded themselves as a positively selected group 
of patients, which could possibly have led to increased cessation rates in this group. 
However, also the control group may have attained this feeling as many of them 
actually believed they were in a group with active treatment due to the standard 
information about the importance of smoking cessation given to all cardiac patients in 
the ward. Not giving informed consent could have abolished these biases, but 
according to the Declaration of Helsinki this is undesirable (83).  
It was not possible to separate the two groups in the ward. Therefore, the 
control group may have been “contaminated” by patients in the intervention group 
passing along important messages from the booklet. Increased focus on smoking 
cessation among staff members due to the present trial may also have increased the 
possibility that the control group received a better standard of care than usual. The 
lack of difference in the smoking cessation rates at hospital discharge and at 6 weeks 
follow up may support this point of view.  
A drop out rate of less than 10% was lower than in comparable studies (53, 
54), and half of the assumed when writing the protocol. Such a low drop out rate 
increases the applicability of the study. However, the drop out rate was higher in the 
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intervention group than in the control group, and this may have been a result of the 
intervention itself. When the participants withdrew they gave various reasons for 
withdrawal: Some changed their mind during hospitalisation because they did not 
want to take part in a study after all, some did not want to quit smoking after all, and 
some were sure they could stay free of smoking without help from others. At time of 
withdrawal, half of the patients stated they had stopped smoking (not verified 
biochemically). In an intention to treat analysis, counting all drop outs as continued 
smokers, the intervention group still had a statistically significant increased cessation 
rate compared to the control group, but the difference of 13% was rather small. 
Biochemical validation of the smoking status is important because some 
patients do not tell the truth about their smoking behaviour (23). There are several 
methods to validate smoking cessation (84, 85). CO measurements in breath or blood 
are inadequate in detecting occasional and light smokers (86). Cotinine measurements 
in serum, saliva or urine is the most widely used method. Cotinine is a metabolite 
from nicotine, and all nicotine products (i.e. patches, gum, snuff) will increase the 
cotinine concentration above the cut-off value for non-smokers. The half life of 
cotinine is approximately 20 hours, and a person who uses nicotine replacements may 
have an increased cotinine concentration for several days after cessation (84, 85). 
Thus, patients using snuff or nicotine replacements were asked to stop this for 10 
days. However, this was difficult to accomplish, and on many occasions we had to 
collect the urine samples after shorter time periods. Thiocyanate measurements would 
have abolished this bias, because thiocyanate is not increased in patients using snuff 
or nicotine replacements as it derives from the cyanide in the tobacco smoke. 
However, thiocyanate measurements has been reported to have a relatively low 
specificity due to its presence in various nourishments (87). After smoking cessation 
its concentration remains elevated for up to a month (88), but in our study this would 
not have posed problems since only two of the quitters stated they stopped smoking 
between 6 and 12 months of follow up. Retrospectively, using thiocyanate 
measurements might have decreased the number of false positive values.   
It could be debated whether continuos abstinence from hospital discharge until 
12 months follow up rather than point prevalence cessation rates at 12 months follow 
up, and whether a longer follow up period would have been more adequate when 
assessing the cessation rates. However, in our trial 93% of the quitters at 12 months 
follow up stopped smoking while hospitalised, and others have found that return to 
smoking after one year is very rare (24). Therefore, we believe our methods in 
assessing the cessation rates were adequate.  
The search for predictors 
In paper II, we tried to evaluate the predictors of smoking cessation using multiple 
logistic regression models. It is debated what to include in this type of analysis (89). 
Including too many variables may turn a variable that is not associated with the 
outcome at all into an independent risk factor, and factors that are closely related may 
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both loose level of significance (89). It is tempting to do many tests, varying the 
inclusion of risk factors, and thereby torture the data until they speak. Ideally, every 
test and method should be planned a priori and stated in the protocol. This is often 
done regarding the primary outcome, but not regarding the secondary outcomes as 
was the case in our protocol. We believe only a limited set of clearly unrelated 
baseline characteristics being significant at the 0.05 level in univariate tests should be 
included in a multivariate test, and have practised this throughout. Further, if finding 
a statistically significant independent risk factor/predictor in a multivariate analysis, 
we have tried not to imply causality (i.e. grey hear is a significant independent risk 
factor for coronary heart disease, but not a causal factor).  
 We also tried to analyse whether the effect of the smoking cessation program 
differed between subgroups. This kind of analysis is performed in order to assess 
whether the treatment suits the patient you are currently dealing with (i.e. is the 
cessation program effective in a patient who still smokes when admitted for his 
second myocardial infarction). There are no consensus regarding such analyses (90), 
and the CONSORT statement includes only a few lines on subgroup analysis (91). 
The problem of multiplicity arises. If you test ten associations, and the null 
hypothesis is true in all associations, the probability of finding one significant 
difference by chance is 0.4 if a significance value of 0.05 is used in each test (1-[1-
0.05]10) (92). Therefore, it is important that every test is prespecified in the protocol, 
that all performed tests are clarified in the paper (not only those with significant 
results), and that proper statistical adjustments for multiplicity are performed. This 
have often not been the case, and serious false conclusions have been made because 
of this (i.e. aspirin is ineffective after ischemic stroke in woman, and tamoxifen is 
ineffective in woman with breast cancer aged <50 years) (90). The only reliable 
statistical approach in subgroup analyses is to test for a subgroup-treatment 
interaction (90). This approach requires widely differing risks of an outcome with or 
without intervention to reach level of significance (90), and trials are seldom powered 
to perform subgroup analyses with acceptable type II error (β)  (90). On basis of these 
limitations regarding subgroup analyses, we first approached the predictors in the 
whole set of data and subsequently analysed a limited number of them in subgroup 
analyses. Power problems may have been the reason why we did not find any 
significant differences between subgroups on cessation rates in the intervention 
versus the control group. But the the assessment of this was probably too ambiguous, 
and the results can at best be regarded as hypothesis-generating.  
The Quality of Life assessment 
It is impossible to randomise patients to either smoking cessation or continued 
smoking. Assessments of QoL improvements in quitters versus sustained smokers are 
therefore difficult to perform, as the results may be biased by unmeasured 
confounders (i.e. patients not able to quit smoking may be a negatively selected group 
with low potential for QoL improvements). Multiple regression analyses have 
commonly been performed in order to adjust for differences in baseline 
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characteristics in non-randomised groups. However, adjustment for all confounders is 
impossible (89), as exemplified by observational data showing that vitamins and 
estrogens reduce cardiovascular mortality, both which have later been refuted by 
randomised trials (93, 94). In contrast to the only other investigation on this topic in 
cardiac patients (66), we only included patients motivated to quit smoking. We may 
therefore have been more successful in adjusting for differences in baseline 
characteristics, and this could explain why our results contradict the findings by Taira 
et. al. (66).  
Significant improvements in physical symptoms in quitters compared to 
sustained smokers may take several years to develop, and it is possible that our 
negative results regarding health-related QoL improvements were due to a too short 
follow up period.   
The cost effectiveness analysis  
The differences in integrals between the survival curves of quitters versus sustained 
smokers translates to the gain in life expectancy if quitting smoking, and the cost per 
life year gained (the cost effectiveness ratio) can easily be calculated. The main 
problem of calculating the cost effectiveness of the smoking cessation program was 
the lack of high quality survival curves in quitters and sustained smokers after a 
coronary event. As explained in the introduction, observational studies on this topic 
tend to underestimate the benefit of smoking cessation. Another problem is the short 
follow up period of most studies. Therefore, methods to estimate survival curves in 
the life time perspective are necessary, but unfortunate these methods are hampered 
by uncertainties (78). 
The patient satisfaction 
Research on communicating messages arousing fear have  shown that such messages 
are effective when they are accompanied by education on how to reduce the health 
threat (95). However, the use of fear arousal message is controversial, and our trial 
has been criticised by health psychologists stating it may provoke defensive 
responses and emotions such as denial of personal risk, hostility, anger and anxiety 
(96, 97). In paper V we seem to have refuted these believes, as the participants in 
general were very satisfied with the cessation program. However, due to the 
following reasons it can be debated whether the patient satisfaction scores 
specifically measured the participants’ feelings regarding the fear arousal message: 
First, the patient satisfaction was recorded 12 months after the introduction of the fear 
arousal message, at which point the anger and hostility, if previously present, might 
have been forgotten. Second, we did not ask the participants specifically how they 
evaluated the fear arousal message. Other elements in the program may have 
outweighed the negative feelings around the fear arousal message. Third, the delivery 
of the message was probably important. The study nurses tried to give the message 
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with empathy, and in a positive way (i.e. if you manage to give up smoking, your risk 
of suffering another heart attack  will be cut down to the half compared with 
continued smoking.). Hence, some of the patients may not have recognised that they 
actually received a fear arousal message.  
Discussion of the main findings 
 
 
 
 
Approximately 80% of the participants did not smoke during the initial 
hospitalisation, and  over 90% of the quitters at 12 months follow up stopped 
smoking while hospitalised. Others have found similar figures (53). Thus, smoking 
cessation programs in patients with coronary heart disease only have to focus on 
relapse prevention. Complicated approaches are probably not necessary. Because the 
intervention and the control group showed similar smoking cessation rates while in 
hospital and at six weeks’ follow up, we speculate that a long follow up period was 
the most important element in the program. This point of view is supported by the 
fact that most smoking cessation trials showing an effect on quit rates in hospitalised 
patients have implemented a long follow up period (36, 51-53), and on the contrary 
that studies with brief interventions have been ineffective (37, 46-48).  
We believe there are three important elements in smoking cessation programs 
in cardiac patients: 
1. You have to inform on the health hazards of continued smoking, thereby 
increasing the patients’ motivation to stay free of smoking (“fear arousal 
message”). It may be important to repeat this information as patients may forget 
and deny. 
2. You have to follow-up the patients for several months. Someone has to care about 
the patients and their smoking behaviour. The patients need to know that someone 
is going to call them, and ask whether they are still free of smoke. 
3. We believe most patients, especially those smoking within 30 min of waking, 
should be offered nicotine replacements and/or bupropion. Further studies are 
needed to determine the efficacy of this strategy.  
The relatively high inclusion rate make our results applicable to an ordinary 
clinical setting. The simple intervention principles, without especially educated 
personnel, should make the program feasible to every cardiac ward.  
“Everything should be made as simple as possible, but not 
simpler.” Albert Einstein. 
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Direct comparison of the cost effectiveness of the smoking cessation program 
against the various medications used in patients with coronary heart disease is not 
straightforward, because the prices of the pharmaceuticals have fallen since their 
respective analyses were performed. But all of the cost effectiveness analyses on 
pharmaceuticals have discounted the costs by approximately 5% per year (98-100). 
Further, most of them have tried to estimate the exact cost per life year gained (98-
101), and not a maximum cost like we did. Therefore, we are confident that the 
smoking cessation program is very cost effective compared to other treatment 
modalities in patients with coronary heart disease.  
Why is the easiest, cheapest and most effective method to reduce mortality not 
part of routine care in most cardiac wards?  Is working with this topic too “low 
technology”, and associated with too low prestige? Is it due to too few resources in 
marketing compared to the pharmaceutical industry? Anyway, we hope the results 
presented in this thesis will be helpful in increasing the implementation of effective 
smoking cessation programs in cardiac clinics, and thereby saving lives world-wide. 
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Pasient nr:                                                                                                       Skjema nr. 2                                   
 
Registreringsskjema. TOBAMI 
 
NAVN, PERSONNUMMER OG ADRESSE :  
 
<Pas.etikett klistres her> 
 
 
Fylles ut av visittgående lege : 
 
Aktuell diagnose (en av fem) :                           Andre opplysninger (sett kryss for 
hvert                                               
                                                                                   spørsmål) :                   
 Ja Nei   Ja Nei
1. Hjerteinfarkt ?     4. Tidl. kjent coronarsykdom ?     
2. Ustabil angina pectoris:    5. Tidl. infarkt ?   
               1. Nyoppstått angina ?    6. Daglig røyker fram til aktuelle  
    sykdom ?  
  
               2. Betydelig 
forverring                       
                   av kronisk angina ?  
    
               3. Hvileangina ?    
3. ACB-opr. ? (Må ha kommet 
direkte fra operasjonsstedet.) 
   
   
   
 
 
                                                                                   Dato:_______ 
                                                                                     
                                                                                   Underskrift:_______________________   
 
 
Skjemaet skal ligge mellom kurve- og medikament-arket i alle pasientpermer på 2C og MINT. 
Det fylles ut på alle pasienter med diagnosene: 
                                                                           -akutt hjerteinfarkt                                                         
                      -ustabil angina pectoris  
                                                                           -ACB-operasjon. 
 
Visittgående lege fyller ut skjemaet på første ordinære visitt etter innkomst (ikke ettermiddagsvisitt 
eller helgevisitt), og markerer dette med et kryss på kurvearket. (TOBAMI............X) 
 
Etter at skjemaet er fylt ut legges det i posthyllen til TOBAMI på avdelingen. 
 
 
 
Participant number:                                                                                                                          
 
Registration form. TOBAMI 
 
 
< Participant label > 
 
 
 
 
 
 
 
 
 
The physicians going rounds are to fill in the following: 
 
The present diagnosis (one of five):                   Some other information (one mark 
per question):                                             
                                                                                                      
 Yes No   Yes No 
1. Heart attack?     4. Previous coronary heart 
disease?   
  
2. Unstable angina:    5. Previous heart attack?   
1. Recent    
development  
of angina? 
   6. Daily smoker until the 
present diagnosis 
  
2. Exacerbation of  
                    chronic angina?      
               
    
               3. Angina at rest?    
3. Coronary bypass surgery?    
   
   
 
 
                                                                                   Date:_______ 
                                                                                     
                                                                                   Signature_______________________   
 
 
 
 
 
 
 
 
Vest-Agder Sentralsykehus 
Medisinsk avdeling. 
 
 
 
 
 
Undersøkelse om røykevaner hos pasienter med hjertesykdom. 
 
Til deg med hjertesykdom. 
 
Vi gjør for tiden en undersøkelse om hjertepasienters røykevaner som vi håper du er villig til 
å være med på. 
 
Alle som er med i undersøkelsen må svare på noen enkle spørsmål, og komme til kontroll om 
ett år.  
Halvparten av dem som er med i undersøkelsen  får spesiell hjelp til å slutte å røyke i form av 
samtaler med sykepleier. 
All informasjon vil bli behandlet konfidensielt og kun brukt til forskning. 
Hvis du ombestemmer deg, og ikke ønsker å være med,  kan du når som helst trekke deg uten 
å måtte oppgi noen grunn.  
 
Det er fint hvis du vil skrive under på at du er villig til å delta i undersøkelsen. 
 
 
På forhånd takk. 
 
 
_______________________                                    ________________________ 
Lege.                                                                         Sykepleier.   
 
 
 
Navn : 
 
Adresse : 
 
Postnr. : 
Poststed : 
Tlf.privat : 
Tlf. mobil : 
Tlf. arbeid : 
 
Vil være med på undersøkelsen:     Ja                  Nei   
 
Dato : _______ 
 
Signatur : ____________________________ 
 
VEST-AGDER 
FYLKESKOMMUNE 
  
Vest-Agder Central Hospital 
Medical Department. 
 
 
 
 
 
Investigation about smoking habits in patients with coronary heart disease 
 
For you with coronary heart disease. 
 
We hope you are willing to participate in this investigation about smoking habits in patients 
with heart diseases. 
 
You have to answer some questions, and attend at the 12 months follow up appointment.  
Half of the participants in this investigation are going to receive special help in quitting 
smoking from a study nurse. 
All the information in this study will be treated strictly confidentially. 
At any time you may withdraw from the trial without further notice.  
 
We hope you are able to join the study and need your written consent. 
 
 
With regards, 
 
 
_______________________                                    ________________________ 
Doctor.                                                                         Nurse.   
 
 
 
Name: 
 
Address: 
 
 
Telephone number: 
 
 
 
 
I participate in the investigation:     Yes                  No   
 
Date : _______ 
 
Signature : ____________________________ 
                                                   
                                            
 
VEST-AGDER 
FYLKESKOMMUNE 
  
Pas.nr.: «Pasnr»                                                                                            Skjema nr. 4 
 
<Pas.etikett> 
 
          Inklusjonsskjema. TOBAMI  
Fylles ut av prosjektsykepleier på alle pasienter som røyker  og er ≤75 år med AMI, UAP 
eller ACB :                    
Inklusjonskriteriene (se baksiden for detaljert beskrivelse) : 
 
 Ja Nei 
1. Daglig røyker fram til aktuelle coronare hendelse ?  (Hvis nei skal resten ikke fylles 
ut) 
  
2. ≤75 år ?   
3. Adresse Vest- Agder eller Aust-Agder ?   
4. Snakker norsk ?   
5. Orientert for tid, sted og situasjon ?   
6. Har ikke alvorlig psykiatrisk sykdom eller alvorlig alkoholisme ?   
7. Har ikke uhelbredelig kreft eller annen alvorlig organsykdom ?    
8. Har AMI, UAP eller ACB ?   
Sett kryss i kun en «Ja»-rubrikk :     
                               8.1. Akutt hjerteinfarkt ? Ja   Nei    
                               8.2. Ustabil angina pectoris :     
                                                 1 Nyoppstått ? Ja   Nei    
                                                 2. Kronisk med forverring ? Ja   Nei    
                                                 3. Hvileangina ? Ja   Nei    
                                8.3. ACB-opr ?  Ja   Nei    
9.  Ønsker å slutte å røyke ?.   
10. Har erklært skriftlig at de ønsker å være med i studien ?.    
 
 
 
 
  
 Ja Nei   
11. Inkludert i TOBAMI ? (Må ha svart «Ja» på alle spørsmål fra 1-10)     
12. Inklusjonsdato :   
13. Hvis nei :  
Spesifiser årsak : 
 
 . 
 
 
Fylles ut på alle inkluderte pasienter : 
14. Randomisert til: (Sett ett kryss i ruten som passer) Intervensjon Kontroll 
   
 
 
 
Participant number:                                                                                             
 
< Participant label> 
 
The inclusion form. TOBAMI  
This form is to be filled in by the study nurse on all patients who smoke and are≤75 years of 
age, and are suffering a heart attack, unstable angina or coronary bypass surgery: 
 
 Yes No 
9. Daily smoker until the start of the present coronary symptoms   
10.≤75 years of age?   
11.Living in Vest- Agder or Aust-Agder?   
12.Are speaking Norwegian?   
13.Oriented regarding the time, the place, and the situation?   
14.Does not have serious psychiatric disease, or alcoholism?   
15.Does not have incurable cancer or serious organ damages?    
16.Does suffer from heart attack, unstable angina or coronary bypass surgery?   
Only mark one question:     
                               8.1. Acute heart attack? Yes  No    
                               8.2. Unstable angina:     
                                                 1 Recent development? Yes  No    
  2. Chronic with       
  exacerbation? 
Yes  No    
                                                 3. Angina at rest? Yes  No    
                                8.3. Coronary bypass surgery?  Yes  No    
9. Does have motivation to quit smoking?   
10. Have signed the written informed consent?    
 
 
 
 
  
 Yes No   
11. Included in TOBAMI ? (Yes on all questions 1-10)     
12. Inclusion date:   
13. If not included, specify why: 
 
 . 
 
 
14. Allocation:  Intervention Control 
   
 
 
 
 
 
 
Pas. nr : «Pasnr»                                                                                                          Skjema nr. 5 
 
<Pas.etikett> 
 
 Personopplysninger. TOBAMI. 
Fylles ut på alle som er inkludert i TOBAMI. 
1.  Ja Nei
Kvinne    11. Røykfritt hjem ? (Må ut for å røyke.)   
Mann      12. Røykfri arbeidsplass ? (Må ut for å røyke.)   
 Ja Nei    
2. Gift eller samboer ?   13. Hvor mange prosent er røykere av de pas. bor 
sammen med? (Sett ett kryss i ruten som passer) : 
3. Hvis ja : Røyker livsledsageren   0-20 20-40 40-60 60-80 >80 
4. Skilt eller separert ?    
5. Enke (mann) ?   14. Hvor mange prosent av arbeidskollegaene røyker 
? 
6. Barn ?   0-20 20-40 40-60 60-80 >80 
7. Utdannelse (sett ett kryss på det som passer):  
1. Grunnskole  15. Antall tidl. røykestopp-forsøk  
2. Videregående    
3. Yrkesskole/fagbrev/ 
fagutdanning/handelsskole 
 Aktuelle innleggelse: 
4. Høyskole   Ja Nei
5. Universitet  16. Røykt under innleggelsen ?   
 
8. Arbeidssituasjon (sett ett kryss på det som passer): 
17. Nikotin-abstinens under innleggelsen ?   (Sett ett 
kyss. Se baksiden for forklaring): 
1. Uføretrygdet  
 
Ingen Lite Middels Mye Svært 
mye 
2. Arbeidsledig   
3. Pensjonert  18. Hvis infarkt : Max. Troponin I  
4. Hjemmeværende  19. Antall døgn innlagt  
5. I arbeid  20. Antall døgn på MINT  
   
  Ja Nei
9. Tidligere sykdommer : 
Antall år med coronarsykdom (sett et kryss i ruten 
som passer) : 
21. Fått antirøykebudskap av lege under 
innleggelsen ? 
  
1. Nyoppstått.  22. Hvis ja: Hvor mange ganger ?  
2. <1 år.  23. Sett hjerte-filmen ?   
3. 1-5 år.  24. Fått brosjyre om AMI/UAP/ACB ?   
4. 6-10 år.     
5. >10 år.     
10. Alkoholforbruk (sett et kryss i ruten som passer) :    
1. Aldri 
2. < 1 drink/pils/glass vin pr dag. 
3. 1-3 d/p/v pr. dag. 
4.  >3 d/p/v pr. dag. 
 
 
 
 
   
 
Participant number:                                                                                                               
 
< Participant label> 
 
 The personal information form. TOBAMI. 
This form is to be filled in on all patients included in TOBAMI. 
1.  Yes No 
Woman    11. Smoking not allowed at home?   
Mann       12. Smoking not allowed at work?   
 Yes No    
2. Married or living with a partner ?   13. The percentage of smokers at home? 
3. If yes: Does the spouse smoke?   0-20 20-40 40-60 60-80 >80 
4. Divorced or separated?    
5. Widow(er)?   14. The percentage of smokers at work? 
6. Children?   0-20 20-40 40-60 60-80 >80 
7. Education (only one mark):  
1. Primary school  15. Number of previous quit-attempts?  
2. High school    
3. Vocational school  The present hospitalisation: 
4. Higher education or university   Yes No 
  16. Smoked during the hospitalisation?   
 
8. Working situation (only one mark): 
17. Nicotine-abstinence during the hospitalisation: 
1. Infirmity  
 
None Little Medium Much Very 
much 
2. Unemployed   
3. Retired  18. If AMI: Max. Troponin I  
4. Working at home  19. The number of days in hospital  
5. Employed  20. The number of days in the intensive 
care unit 
 
   
  Yes No 
9. Previous diseases: 
The number of years with coronary heart disease 
(only one mark): 
21. Received advise not to smoke from a 
doctor? 
  
1. Recently discovered  22. If yes: How many times?  
2. <1 year  23. Seen the heart movie?   
3. 1-5 years  24. Received booklet on 
AMI/UAP/CABG? 
  
4. 6-10 years     
5. >10 years     
10. Alcohol consumption (only one mark):    
1. Never 
2. < 1 beverage per day 
3. 1-3 beverage per day 
4.  >3 beverage per day 
 
 
 
 
   
 
Pas. nr.: «Pasnr»                                                                                               Skjema nr. 6 
 
<Pas.etikett> 
 
Røykestatus. TOBAMI. 
 
 
Fylles ut på alle som er inkludert i TOBAMI. 
 
 
1. Type tobakk (sett kryss på det som passer):  
1. Ferdig sigaretter. 
2. Rullings 
3. Pipe. 
4. Sigarer/sigarillos. 
 
2. 
 
1. Antall sig./sigarer dgl. i gj.snitt i den tiden 
pas. har røykt. 
 
2. Hvis pipe: Ant. pakker tobakk pr. uke  
  
3.  
Antall år pas. har røykt.  
 
4. Hvis ferdigsigaretter/rullings: 
Med filter      Uten filter  
 
 
 
5. Ja Nei 
Har pasienten røykt siste 24 t. før 
innleggelsen ? 
  
 
6. 
  
Antall sig./piper/sigarer dgl i gj.snitt 
siste uka. 
 
   
 
 
 
 
 
 
 
 
 
 
 
Participant number:                                                                                                
 
< Participant label> 
 
Smoking habits. TOBAMI. 
 
 
 
 
1. Type of tobacco:   
1. Pre-made cigarettes 
2. Self-rolling cigarettes 
3. Pipe 
4. Cigar 
 
2. 
 
1. Mean number of cigarettes/cigars per day 
since started smoking 
 
2. If pipe: The number of packs of tobacco per 
week 
 
  
3.  
The number of years of smoking  
 
4. If cigarettes: 
With filter      Without filter  
 
 
 
5. Yes No 
Smoked the last 24 hours before 
admission? 
  
 
6. 
  
Mean number of 
cigarettes/cigars/pipes per day the last 
week before admission? 
 
   
 
 
 
 
 
 
 
 
 
 
Pas. nr.: «Pasnr»                                                                                                   Skjema nr. 7 
 
<Pas.etikett>                                      Fagerstrøm 
                            Sett ring rundt 
                            det som passer: 
1. 
Hvor mange sigaretter røyker du pr. dag ? 
 
0-15 
16-24 
25 eller mer 
 
 
0 
1 
2 
2. 
Hvor lang tid etter at du våkner tenner du din første 
sigarett ? 
 
Innen 30 min 
Etter 30min 
 
 
1 
0 
3. 
Røyker du mer om morgenen enn senere på dagen ? 
 
Ja 
Nei 
 
 
1 
0 
4. 
1.  Hvis du røyker ferdigsigaretter : 
Hvilket nikotininnhold har sigarettmerket du 
røyker ?                  
 
 2. Hvis du ruller egne sigaretter eller røyker pipe: 
Hvilken type tobakk bruker du ? 
(Alle typer hylser med filter reknes også som ekstra 
mild) 
 
≤ 0,8 mg 
0,9-1,2 mg 
> 1,2 mg 
 
 
Ekstra mild (<2 mg). 
Mild (2-2,5 mg). 
Sterkere type (>2,5 mg). 
 
 
0 
 
1 
2 
 
0 
1 
2 
5. 
Har du problemer med å la være å røyke i situasjoner 
der røyking er forbudt (kino, teater, mm.) ? 
 
Ja 
Nei 
 
 
1 
0 
6. 
Røyker du selv om du er så syk at du nå og da er 
sengeliggende ? 
 
Ja 
Nei 
 
 
1 
0 
7. 
Hvilken sigarett er det vanskeligst å unnvære ? 
 
Morgenens første ? 
En senere på dagen ? 
 
 
1 
 
0 
8. 
Inhalerer du røyken ? 
 
Alltid 
Iblant 
Aldri 
 
 
2 
1 
0 
 
 
 
 
Participant number:                                                                                                         
 
< Participant label>                      
 
The Fagerstrom score 
                             
 
1. 
Number of cigarettes per day ? 
 
0-15 
16-24 
25 or more 
 
 
0 
1 
2 
2. 
The time to the first cigarette in the morning? 
 
Within 30 min 
After 30min 
 
 
1 
0 
3. 
Do you smoke more in the morning than later in the 
day? 
 
Yes 
No 
 
 
1 
0 
4. 
1.  If you smoke pre-made cigarettes: 
What is the nicotine content per cigarette?        
 
 
 2. If you role your own cigarettes or smoke a pipe: 
What type of tobacco do you use? 
 
≤ 0,8 mg 
0,9-1,2 mg 
> 1,2 mg 
 
 
Extra mild (<2 mg). 
Mild (2-2,5 mg). 
Stronger type (>2,5 mg). 
 
 
0 
 
1 
2 
 
0 
1 
2 
5. 
In places where smoking is prohibited, do you have 
problems in not to smoke? 
 
Yes 
No 
 
 
1 
0 
6. 
Do you smoke when you are confined to bed because 
of sickness? 
 
Yes 
No 
 
 
1 
0 
7. 
Which cigarette is hardest to avoid? 
 
The first one in the 
morning? 
One later in the day? 
 
 
1 
 
0 
8. 
Do you inhale the smoke? 
 
Always 
Sometimes 
Never 
 
2 
1 
0 
 
 
Pas. nr.: «Pasnr»                                                                                                Skjema nr. 8  
 
<Pas.etikett> 
Motivasjon og Tilbakefall. TOBAMI. 
Hvor sikker er du på at du vil unngå å røyke i følgende situasjoner ?  
(Sett ett kryss for hvert spørsmål.)   
 
 
1. Når jeg føler meg utålmodig ? 
Usikker Litt usikker Hverken 
eller 
Litt sikker Sikker Meget 
sikker 
Svært sikker
       
 
 
 
2. Når jeg venter på noe eller noen ?  
Usikker Litt usikker Hverken 
eller  
Litt sikker Sikker Meget 
sikker 
Svært sikker
       
 
 
 
3. Når jeg føler meg frustrert ? 
Usikker Litt usikker Hverken 
eller 
Litt sikker Sikker Meget 
sikker 
Svært sikker
       
 
 
 
4. Når jeg er bekymret ? 
Usikker Litt usikker Hverken 
eller 
Litt sikker Sikker Meget 
sikker 
Svært sikker
       
 
 
 
5. Når jeg er sulten eller har lyst på noe godt ? 
Usikker Litt usikker Hverken 
eller 
Litt sikker Sikker Meget 
sikker 
Svært sikker
       
 
 
 
6. Når jeg ønsker å bli i godt humør ? 
Usikker Litt usikker Hverken 
eller 
Litt sikker Sikker Meget 
sikker 
Svært sikker
       
 
 
 
7. Når jeg ønsker å få tiden til å gå ? 
Usikker Litt usikker Hverken 
eller 
Litt sikker Sikker Meget 
sikker 
Svært sikker
       
 
 
 
8. Når noen tilbyr meg en sigarett ? 
Usikker Litt usikker Hverken 
eller 
Litt sikker Sikker Meget 
sikker 
Svært 
sikker 
       
 
 
 
9. Når jeg drikker alkohol ? 
Usikker Litt usikker Hverken 
eller 
Litt sikker Sikker Meget 
sikker 
Svært 
sikker 
       
 
 
 
10. Når jeg føler meg utilpass ? 
Usikker Litt usikker Hverken 
eller 
Litt sikker Sikker Meget 
sikker 
Svært 
sikker 
       
 
 
 
11. Når jeg er i en situasjon der jeg føler røyking er en del av mitt selvbilde ? 
Usikker Litt usikker Hverken 
eller 
Litt sikker Sikker Meget 
sikker 
Svært 
sikker 
       
 
 
 
12. Hvor sikker er du på at du er røykfri om 1 år ?  
( Sett et kryss i rute 1-10. 1=jeg er i tvil om jeg er røykfri. 10=helt sikker). 
 
I tvil                                                                                                                     Helt sikker 
1 2 3 4 5 6 7 8 9 10 
 
 
13. Hvor sterkt ønsker du å slutte å røyke for alltid ?  
( Sett et kryss i rute 1-10. 1=jeg er i tvil om jeg virkelig ønsker å slutte. 10=veldig sterkt.). 
 
I tvil                                                                                                                  Veldig sterkt 
1 2 3 4 5 6 7 8 9 10 
 
 
 
Participant number:                                                                                                            
 
<Participant label> 
Motivation and Relapse. TOBAMI. 
How confident are you in resisting smoking in the following situations?  
(Only one mark per question)   
 
 
1. When I feel impatient? 
Completely 
unsure 
A bit unsure Neither sure 
nor unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
 
 
2. When I am waiting for someone or something ?  
Completely 
unsure 
A bit unsure Neither sure 
nor unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
 
 
3. When I fell frustrated ? 
Completely 
unsure 
A bit unsure Neither sure 
nor unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
 
 
4. When I am worried ? 
Completely 
unsure 
A bit unsure Neither sure 
nor unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
 
 
5. When I am hungry or want something good to eat? 
Completely 
unsure 
A bit unsure Neither sure 
nor unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
 
 
6. When I want to cheer up? 
Completely 
unsure 
A bit unsure Neither sure 
nor unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
 
 
7. When I am trying to pass time? 
Completely 
unsure 
A bit unsure Neither sure 
nor unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
8. When someone offers me a cigarette ? 
Completely 
unsure 
A bit 
unsure 
Neither 
sure nor 
unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
 
 
9. When I am drinking an alcoholic beverage ? 
Completely 
unsure 
A bit 
unsure 
Neither 
sure nor 
unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
 
 
10. When I feel uncomfortable 
Completely 
unsure 
A bit 
unsure 
Neither 
sure nor 
unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
 
 
11. When I am in a situation in which I feel smoking is a part of my self-image? 
Completely 
unsure 
A bit 
unsure 
Neither 
sure nor 
unsure  
A bit sure Sure Very sure Absolutely 
sure 
       
 
 
 
12. How confident are you in being free of smoking one year ahead ?  
 
Not confident                                                                                          Absolutely confident 
1 2 3 4 5 6 7 8 9 10 
 
 
13. How much do you want to stop smoking forever?  
 
In doubt                                                                                                    Very much want to 
1 2 3 4 5 6 7 8 9 10 
 
 
 
Pas. nr.: «Pasnr»                                                             
                      Dato: 
 <Pas.etikett> 
Livskvalitet  
 
 
1. Hvor ofte i løpet av den siste måneden har din helse begrenset din  sosiale aktivitet ? 
(Som f.eks. besøk hos venner eller nære slektninger.)  
 
Ikke i det hele 
tatt 
Noen få 
ganger 
Av og til Ganske ofte For det meste Hele tiden 
      
 
 
2. Alt i alt, hvordan vil du bedømme ditt sosiale liv den siste måneden ? 
Jeg har vært : 
 
Svært  
fornøyd 
Litt     
fornøyd 
Verken 
fornøyd eller 
misfornøyd 
Litt 
misfornøyd 
Svært 
misfornøyd 
 
     
 
 
3. Har du følt deg frisk nok til å gjøre det du ønsket å gjøre den siste måneden ? 
 
Ja, absolutt For det meste Problemer med 
helsen har 
begrenset meg på 
noen viktige 
områder 
Jeg har bare vært 
frisk nok til å ta 
vare på meg selv 
Jeg har trengt 
hjelp til det 
meste av det jeg 
ønsket å gjøre 
     
 
 
4. Hvor lenge (hvis i det hele tatt) har helsen begrenset deg i hver av følgende aktiviteter: 
 
 
 
Ikke begrenset 
meg i det hele 
tatt 
Begrenset meg  i 
mindre enn 3 
mndr 
Begrenset meg  i 
mer enn 3 mndr 
Kraftig fysisk aktivitet som tunge løft, 
løping eller fysisk krevende idrett. 
 
 1 
 
 2  
 
 3 
Moderat fysisk aktivitet som å flytte et 
bord, bære handleposer, e.l. 
 
 1 
 
 2 
 
 3 
Gå opp en bakke eller noen få trapper.  1  2  3 
Gå 500 m på flat mark.  1  2  3 
Spise, kle på seg eller gå på toalettet  1  2  3 
 
 
 
 
 
5.  Personer med hjertesykdom får av og til noen av følgende symptomer. Sett et kryss  i 
hver rad for å angi hvor ofte du har hatt disse symptomene siste måned. 
 
SYMPTOMER Hver dag Flere 
dager i 
uka 
Ca. en 
gang 
pr.uke 
2-3 ggr. 
pr. 
måned.  
Ca. en 
gang pr. 
måned 
Ikke i det 
hele tatt. 
Trøtthet       
Svimmel       
Glemsk       
Hjertebank       
Brystsmerter       
Konsentrasjonsvanske
r 
      
Tung pust       
Synsforstyrrelser       
Søvnvansker       
 
 
 
 
6. For hvert av spørsmålene nedenfor ønsker vi at du markerer det svaret som passer 
best med hvordan du har følt deg siste måned. 
 
SYMPTOMER Hele 
tiden 
For det 
meste 
Ganske 
ofte 
Av og til En 
sjelden 
gang 
Ikke i det 
hele tatt 
Hvor ofte har du følt deg 
nervøs eller urolig den 
siste måneden ? 
 
 
 
 
 
 
 
 
 
 
 
 
Hvor ofte har du følt deg 
rolig og avslappet den 
siste måneden ? 
 
 
 
 
 
 
 
 
 
 
 
 
Hvor ofte har du vært lei 
deg eller  mismodig den 
siste måneden ? 
 
 
 
 
 
 
 
 
 
 
 
 
Hvor ofte har du følt deg 
lykkelig den siste 
måneden ? 
 
 
 
 
 
 
 
 
 
 
 
 
Hvor ofte i løpet av den 
siste måneden  har du følt 
deg så nedtrykt at 
ingenting kunne få deg i 
godt humør ?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Denne stigen  symboliserer livets stige. Øverste trinn         
    representerer det best mulige liv for deg. Nederste     
    trinn representerer det verst mulige liv for deg.                Best mulige liv 10 
   9 
                                                                                                      8 
    1. På hvilket trinn føler du at du står for tiden ?   7 
                                                              FOR TIDEN  (1-10)     6 
   5 
    2. På hvilket trinn sto du for ett år siden ?   4 
    FOR ETT ÅR SIDEN (1-10)   3 
   2 
    3. Hvis du tenker framover, på hvilket trinn tror du at    Verst mulige liv 1 
        du står om fem år ?    
                 OM FEM ÅR (1-10)    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant number:                                                             
                      Date: 
 < Participant label> 
The Quality of Life 
 
 
1. How much of the time during the past month has your health limited your social 
activities (like visiting with friends or close relatives)  
 
None of the 
time 
A little of the 
time 
Some of the 
time 
A good bit of 
the time 
Most of the 
time 
All of the 
time 
      
 
 
2. All things considered, how satisfied have you been with your social life during the last 
month? 
 
Very satisfied Fairly 
satisfied 
Neutral or 
mixed 
feelings 
Somewhat 
satisfied 
Very satisfied 
 
     
 
 
3. Did you feel healthy enough to do the things you wanted to do during the last month? 
 
Yes-definitely so For the most part Health problems 
limited me in 
some important 
ways 
I was only 
healthy enough 
to take care of 
myself 
I needed 
someone to help 
me with most or 
all of the things I 
had to do 
     
 
 
4. For how long (if at all) has your health limited you in each of the following activities? 
 
 
 
Not limited me 
at all 
Limited me for 
3 months or less 
Limited me for 
more than 3 
months 
Vigorous activities, like lifting heavy 
objects, running, or participating in 
strenuous sports 
 
 1 
 
 2  
 
 3 
Moderate activities, like moving a 
table, carrying groceries or bowling 
 
 1 
 
 2 
 
 3 
Walking uphill or climbing a few 
flights of stairs 
 1  2  3 
Walking one block  1  2  3 
Eating, dressing, bathing, or using the 
toilet 
 1  2  3 
 
 
 
5.  How often did you experience the following symptoms during the last month? 
 
SYMPTOMS Every day Several 
days a 
week 
About 
once a 
week 
2-3 times 
a month 
About 
once a 
month 
Not at all 
Tired       
Dizzy       
Forgetful       
Irregular heart beats       
Chest pain       
Problems 
concentrating 
      
Shortness of breath       
Blurred vision       
Trouble sleeping       
 
 
 
 
6. For each of the following questions, please mark the answer that comes closest to the 
way you have been feeling during the past month 
 
SYMPTOMS All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
None of 
the time 
How much of the time 
have you been a nervous 
person? 
 
 
 
 
 
 
 
 
 
 
 
 
How much of the time 
have you felt calm and 
peaceful? 
 
 
 
 
 
 
 
 
 
 
 
 
How much of the time 
have you felt down-
hearted and blue? 
 
 
 
 
 
 
 
 
 
 
 
 
How much of the time 
have you been a happy 
person? 
 
 
 
 
 
 
 
 
 
 
 
 
How often have you felt 
so down in the dumps 
that nothing could cheer 
you up? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Here is a ladder representing the ”ladder of life”.               
    The top of the ladder represents the best possible life     
     for you, The bottom of the ladder represents the worst
     possible life for you.      
      Best possible life 10 
        9 
                                                                                                      8 
    1. On which step of the ladder do you feel you stand at   7 
        present time?                         PRESENT TIME  (1-10)    6 
   5 
    2. On which step would you have stood five years ago?   4 
      FIVE YEARS AGO (1-10)   3 
   2 
    3. Thinking about your future, on which step do you          Worst possible life 1 
        think you will stand about five years from now?    
                         FIVE YEARS FROM NOW (1-10)    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pas. nr.: «Pasnr»        Skjema nr 14 
 
<Pas.etikett>                                         Dato:  
Sluttskjema. TOBAMI 
 
Fylles ut på alle inkluderte pasienter ved sluttkontrollen. 
 
Hendelser siste året (Fra utskrivelsen til sluttkontrollen etter ca. et år)  : 
 
1. Ja Nei 
      1. Død ?   
      2. Hvis død :   
         Cardial årsak ?   
   
2. Drop out ?   
    Hvis ja, spesifiser årsak :   
 
 
  
3. Antall sykehuskonsultasjoner.  
4. Antall telefonsamtaler.  
5. Antall polikliniske konsultasjoner.  
6. Antall AMI.  
7. Antall sykehusinnleggelser pga 
hjertesykdom. 
 
 Ja Nei 
8. ACB operert ?     Til alle:   
9. PTCA ?    16. Antall tilbakefall ?    
10. Fått diagnosen hjertesvikt ?    (Def.: Ant. perioder med daglig 
røyking.) 
  
     Ja Nei
11. Røykte pas. ved 6-ukers-ktr. ?       17. Er hjemmet røykfritt ved sluttktr. ?   
12. Påstår pas. at han/hun har sluttet å 
røyke ved sluttktr. ? 
   18. Røyker livsledsager ved sluttktr. ?   
               Hvis ja :    19. Ant. min. brukt på pas.konsult.:    
13.          S-Cotinine-verdi :                      1. Under innleggelsen   
14. Når sluttet pas. å røyke ? (Sett ett kryss på det som       
passer):  
                   2. Etter utskrivelsen     
     1. Under innleggelsen ved 
inklusjonen 
  20. Nikotinsubstitusjon:   
     2. <1 mnd etter utskrivelsen                1. Ant. uker med plaster   
     3. 1-3 mndr etter utskrivelsen                2. Ant. uker med tyggegummi   
     4. 3-6 mndr etter utskrivelsen                3. Ant. uker med annen type   
     5. 6-12 mndr etter utskrivelsen      
   Hvis pas. fremdeles røyker :      
15. Hvor mange sig./piper el. sigarer      
Røyker pas. daglig ved sluttkontrollen ?   
 
 
Participant number:         
 
<Participant label>                                         Date:  
End of study. TOBAMI 
 
Events from discharge until 12 months follow up: 
 
1. Yes No 
      1. Dead?   
      2. If yes:   
         Cardiac cause?   
   
2. Drop out?   
    If yes, the cause of withdrawal:   
 
 
  
3. Number of hospital admissions:  
4. Number of telephone calls from study 
nurse: 
 
5. Number of out-patient visits with 
study nurse: 
 
6. Number of AMI:  
7. Number of admissions due to heart 
disease: 
 
   
8. Bypass surgery?       
9. Percutaneous coronary intervention?    16. Number of relapses with daily 
smoking? 
  
10. Diagnosed heart failure?       
     Yes No 
11. Smoked at 6 weeks?       17. Smoking forbidden at home?    
12. Stopped smoking at 12 months (end 
of study? 
   18. Does the spouse smoke at end of 
study? 
  
               If yes:    19. Number of minutes used in the 
intervention:  
  
13.          U-Cotinine:                      1. During hospitalisation:   
14. When did the participant stopped smoking?:                     2. After discharge:     
     1. During the initial hospitalisation   20. Nicotine replacements:   
     2. <1 month after discharge   1. Number of weeks with        
                   patches: 
  
     3. 1-3 months after discharge   2. Number of weeks with     
gums: 
  
     4. 3-6 months after discharge   3. Number of weeks with 
another kind: 
  
     5. 6-12 months after discharge      
   If still smoking:      
15. Number of cigarettes per day:      
 
Pas. nr.: «Pasnr»                                         
 
<Pas.etikett> 
                                       Dato:    
 
Evalueringsskjema. TOBAMI. 
 
Vi ønsker at du svarer så ærlig du kan på følgende spørsmål. (Sett ett kryss for hvert spørsmål.) 
 
 
1.    Hvordan synes du det siste året har vært i forhold til tidligere år når det gjelder din 
       hjertesykdom ? 
 
Svært mye verre Ganske mye 
verre 
Hverken bedre 
eller verre 
Ganske mye 
bedre 
Svært mye bedre
     
 
 
2.     I hvor stor grad har du fra sykehuset fått informasjon om røykens virkning på 
hjertet ? 
 
Svært liten grad  Liten grad Middels grad Høy  grad Svært høy grad 
     
 
 
3.     I hvilken grad har legen anbefalt deg å slutte å røyke ? 
 
I svært liten grad I liten grad I middels grad I høy  grad I svært høy grad 
     
 
 
4.     I hvilken grad har annet helsepersonell anbefalt deg å slutte å røyke ? 
 
I svært liten grad I liten grad I middels grad I høy  grad I svært høy grad 
     
 
 
5.     I hvilken grad har du blitt hjulpet av sykehuset til å slutte røyke ? 
 
I svært liten grad I liten grad I middels grad I høy  grad I svært høy grad 
     
 
 
6.     Hvor fornøyd er du alt i alt med hjelpen du har fått fra sykehuset til å slutte å 
røyke ? 
 
Svært lite 
fornøyd 
Lite fornøyd Middels fornøyd Veldig fornøyd Svært fornøyd 
     
 
 
 
 
7.     I hvilken grad har du blitt hjulpet av familie og venner til å slutte å røyke ? 
 
I svært liten grad I liten grad I middels grad I høy  grad I svært høy grad 
     
 
 
 
Til deg som har sluttet å røyke: 
 
8. Mener du at du hadde vært røykfri i dag hvis du ikke hadde fått hjelp fra  sykehuset ? 
 
Ja, helt sikkert Ja, sannsynligvis Vet ikke Nei, 
sannsynligvis 
ikke 
Nei, helt sikkert 
ikke 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant number:                                         
 
<Participant label> 
                                       Date:    
 
Evaluation form. TOBAMI. 
 
Please be as honest as possible when answering the following questions (only one mark per 
question): 
 
 
1.    Compared to previously, how do you feel the last year has been regarding your 
heart disease? 
 
Very much 
worse 
Quite much 
worse 
Neither worse 
nor better 
Quite much 
better 
Very much better
     
 
 
2.     Regarding the tobaccos effect on your heart, to what degree have you been 
informed about this from the hospital? 
 
Very low degree Low degree Neither low nor 
high 
High degree Very high degree
     
 
 
3.     To what degree did the doctor recommend you to stop smoking? 
 
Very low degree Low degree Neither low nor 
high 
High degree Very high degree
     
 
 
4. To what degree have other health personnel recommended you to stop smoking?  
 
Very low degree Low degree Neither low nor 
high 
High degree Very high degree
     
 
 
5.     To what degree do you feel you have been helped from the hospital in quitting 
smoking?  
 
Very low degree Low degree Neither low nor 
high 
High degree Very high degree
     
 
 
 
 
6.     All in all, how satisfied are you with the help you have received from hospital in 
quitting smoking? 
 
Very little 
satisfied 
Little satisfied Medium satisfied Much satisfied Very much 
satisfied 
     
 
 
 
7. To what degree do you feel you have been helped from family and friends in quitting 
smoking? 
 
Very low degree Low degree Neither low nor 
high 
High degree Very high degree
     
 
 
 
For you who have managed to stop smoking: 
 
8. If you had not received any help from the hospital in smoking cessation, do you 
believe you had been free of smoking today? 
 
Yes, absolutely Yes, probably Do not know No, probably not No, absolutely 
not 
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En hjelp til røykeslutt
- for deg som virkelig trenger det
Det er viljen som det gjelder
Viljen frigjør eller feller
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10.3    Bivirkninger
Ved for mye nikotin: Blekhet, svetting, økt spyttdannelse,
kvalme, oppkast, diaré, hodepine.
Ved plaster: Lokale hudreaksjoner.
Ved tyggegummi: Hikke (ved for rask tygging), irritasjon i
munn og svelg og magesmerter. Tyggegummien kan feste seg
til tannproteser og gjøre skade.
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1. KJÆRE
1
Du har nettopp gjennomlevd et hjerteinfarkt, et kraftig anfall
med hjertekrampe eller en hjerteoperasjon. Dette oppleves
dramatisk av de fleste og mange tenker: 
• Hva med framtidsutsikter? 
• Hvordan blir livet etter dette? 
• Hva kan jeg gjøre og hva må jeg unngå? 
• Hvilken hverdag får jeg? 
Få tilstander er så grundig utforsket av medisinsk ekspertise
som hjertesykdom. Vi vet i dag svært mye om hvordan vi
kan hjelpe deg. All utredning, medisinering og behandling
har som hovedmål at du skal unngå å oppleve det samme
igjen. Vi som jobber med dette merker at den medisinske
utviklingen gir gode resultater. Behandlingen er betraktelig
bedre i dag enn for bare få år siden! 
Mange røykere opplever det samme som deg. Hjerteinfarkt
er fremdeles en typisk røykesykdom.
Men nå til det positive: Du ønsker å slutte å røyke! 
Din største motivasjon er sannsynligvis at du ikke ønsker å
oppleve det samme igjen. Røykeslutt er det viktigste du
kan gjøre får å unngå nye hjerteanfall. Ingen av de medis-
iner eller behandlinger vi rår over i dag gir bedre effekt enn
røykestopp når det gjelder å forebygge det du nettopp har
gjennomlevd. Så selv med dagens høyteknologiske medisin
må vi innrømme at det du selv kan gjøre er viktigere enn det
vi kan gjøre for deg. Det betyr ikke at det vi gjøre er uvirk-
somt. Nei, det er tvertimot meget effektivt. Det er bare det at
røykestopp vanligvis er dobbelt så effektivt som medisinene
når det gjelder å forebygge nye hjerteanfall.
Nå har vi aldri sagt at røykestopp er enkelt. Nettopp derfor
engasjerer vi oss og vil hjelpe deg med den motivasjonen du    
har. Vi vet litt om hva de som slutter å røyke sliter med. Kan
vi hjelpe deg til å bli røykfri, har vi hjulpet deg på beste måte. 
Røykestopp er ikke enkelt, men det er viktig
Vi håper denne brosjyren og den hjelp du ellers får ved Vest-
Agder Sentralsykehus kan motivere til å leve videre uten
tobakk. 
Lykke til !
Hilsen
Tone Bæck, sykepleier.               Finn Tore Gjestvang, 
seksjonsoverlege, hjerteavd.         
Eva Borøy, sykepleier.                 Petter Quist Paulsen, 
ass.lege.  
Dette heftet er utarbeidet av: Tone Bæck
Frode Gallefoss
Finn Tore Gjestvang
Eva Borøy
Petter Quist Paulsen
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2. LITT OM TOBAKK OG HELSE-
SKADER
3
Vi vet i dag at halvparten av de som røyker dør for tidlig 
pga. røyking. Røyking kan føre til forskjellige kreftsyk-
dommer, spesielt i lunger, munnhule, spiserør, magesekk,
nyrer og urinblære. Men den fører først og fremst til karsyk-
dommer som hjertekrampe, hjerteinfarkt og hjerneslag.
4Det som kommer nå er hard kost for mange. Men som helse-
personell føler vi plikt til å legge fakta på bordet, og fortelle
hvor skadelig røyken er for hjertet. 
Mange holder seg friske i mange år selv om de røyker. Noen
får aldri røyke-relatert sykdom.
Dessverre har du fått hjertesykdom. Det er et slags bevis på
at hjertet ditt ikke tåler røyken. 
Røyking fører til :
1.  Tette blodårer til hjertemuskelen
Blodårene rundt hjertet forsyner hjertemuskelen med blod.
Røyking fører til at veggen i disse blodårene blir tykkere, og
at det dermed blir mindre plass til blodet. Dette er forandr-
inger som kommer over flere år, og det kalles åreforkalkning.
Når blodkarene går nesten tett får man hjertekrampe (angina
pectoris) og når de går helt tett får man hjerteinfarkt.
Figur 1
3. RØYKING OG HJERTESYKDOM
Åreforkalkning
Nesten tett kar 
fører til 
hjertekrampe
2.  Klebrige blodplater 
Blodplatene sørger for at blodet levrer seg og at det dannes
blodpropp. Straks etter man har tent en røyk påvirkes blod-
platene i kroppen slik at de blir mere klebrige. De kan da 
feste seg til den fortykkede åreveggen i blodkarene, og tette
igjen disse. Skjer det i blodårene rundt hjertet, får man et
hjerteinfarkt.
Figur 2
3.  Hjerterytmeforstyrrelse
Nikotinen i tobakken påvirker hjertet slik at pulsen øker med
10-15 slag per minutt. Noen hjertemedisiner som gis etter
hjerteinfarkt skal senke pulsen for at hjertet skal gå roligere.
Virkningen av disse medisinene oppveies av fortsatt røyking.
Man ser også av og til at røyking utløser hjerterytmeforstyrr-
elser. Disse kan være alvorlige.
5
Åreforkalkning
med blodpropp
Helt tett kar fører 
til hjerteinfarkt
Det er flere ting som kan bidra til den type hjertesykdom du
nå opplever. Vi vet f.eks. at røyking, arvelige forhold, høyt
kolesterol og høyt blodtrykk øker risikoen.
Det er selvfølgelig dumt hvis du har fått din hjertetilstand
pga. røyking. Men når du nå først har fått det, er det viktig at
du har en risikofaktor som kan fjernes. Hvis du tar bort din
risikofaktor "røyking", så er dine leveutsikter dramatisk
endret sammenliknet med hvis du fortsetter å røyke. En lang
rekke både norske og internasjonale undersøkelser viser at
effekten av røykestopp hos personer med hjertesykdom er
meget god. Denne effekten kommer med en gang man 
slutter å røyke. Hvis du slutter å røyke har du allerede etter
1-2 år 40-60% mindre risiko for nytt hjerteinfarkt og død
enn om du fortsetter. Ingen av medisinene vi gir deg har 
tilnærmelsesvis så god effekt. De fleste medisiner vi gir 
i dag reduserer din risiko for nytt hjerteinfarkt med dødelig
utgang de neste 5 årene med bare ca 30-40%
Figur 3
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4. LITT STATISTIKK TIL DIN    
FORDEL
Risiko for død 5 år etter hjerteinfarkt
- 62 % lavere 
risikoRelativ 
Risiko
ved fortsatt røyking
ved røykeslutt
Jo lengre du holder deg røykfri, jo større blir effekten. Det
viser denne figuren: 
Figur 4
Denne undersøkelsen viste at hele 63 % av dem som sluttet 
å røyke levde etter 13 år. Av dem som fortsatte å røyke var
18 % i live etter 13 år.
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Forløpet etter hjerteinfarkt eller 
hardt angina-anfall.
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Sluttet å røyke
Fortsatte å røyke
År etter hjerteinfarkt eller angina.
85. LITT OM NIKOTIN-
AVHENGIGHET
Nikotin skaper avhengighet. Det kan være flere forhold som
gjør det vanskelig å slutte å røyke. Det kan være at du blir
rastløs og urolig når du kutter ut røyken. Kroppen blir vant
til nikotinen og reagerer når nikotinnivået synker (fysisk abs-
tinens). Det kan også være at du lengter etter «magadraget»
fordi man setter pris på den umiddelbare effekten av nikotin-
en som treffer hjernen 7 sekunder etter at røyken er pustet
inn (psykisk abstinens).
Det er altså to typer nikotinabstinens
1.  Fysisk abstinens
Symptomer: 
Hodepine, tretthet, skjelving, søvnproblemer, konsentra-
sjonsvansker, svettetokter, svimmelhet, irritasjon, angst,
depresjon.
Disse symptomene er verst de første 2-3 dagene etter
røykestopp. Deretter avtar de gradvis, og etter 2- 4 uker er
den fysiske abstinensen over. Når du leser dette, har du
gjennomlevd de mest plagsomme fysiske abstinensproblem-
er i forbindelse med din røykeslutt.
Du er altså allerede over den fasen som de fleste opplever
som mest plagsom. Det du da må kjempe mot er psykiske
abstinensplager.
2.  Psykisk abstinens
Røykesug er et eksempel på psykisk abstinens. Hjernen din
vil lenge huske hvor godt det var med en røyk. Du vil derfor
ofte få lyst på røyk, selv lenge etter at den fysiske abstinens-
en er over. Noen drømmer om «magadraget» mange år etter
at de har sluttet å røyke. Husk da at røykesuget ofte er veldig
impulspreget («må ha en røyk akkurat nå») og situasjons-
betinget, og pleier å forsvinne etter bare 3-4 minutter. 
I så fall er halve jobben gjort ! Den verste abstinensfasen er
over. Hvis du ikke har vært plaget med fysiske abstinenssym-
ptomer på sykehuset, får du det sannsynligvis heller ikke! (Du
kan imidlertid fremdeles bli plaget med situasjonsbetinget
røykesug.)
Du kan nå konsentrere deg om å unngå tilbakefall.
6. HAR DU VÆRT RØYKFRI UNDER 
INNLEGGELSEN ?
9
7.1   Det aller viktigste: 
Prøv ALDRI «bare én sigarett». 
Undersøkelser viser at hvis du bare tar en sigarett, er sjansen
for tilbakefall stor selv etter mange år! 
Det er altså mye som tyder på at en bør tenke: «En gang
røyker, alltid røyker». En sigarett på julaften, nyttårsaften ell-
er 17.mai er ofte første skritt på vei mot tilbakefall.
Denne figuren viser hvor mange som forblir røykfrie etter
røykestopp:
Vi ser at etter 4 måneder flater kurven ut. Dvs. at greier du de
fire første månedene, er sannsynligheten stor for at du vil
mestre dette.
7.2    Andre viktige momenter
Det er gjort flere hundre internasjonale undersøkelser om røyke-
stopp. Her følger en liste over det som har vist seg å være 
viktigst for å unngå tilbakefall. Ikke alt vil passe for deg, men
kanskje finner du noen punkter som vil kunne hjelpe deg.
1. Hvis din livsledsager røyker er det vanskelig å lykkes.  
Prøv å overtale partneren til å slutte sammen med deg. 
Ta gjerne han/hun  med på samtalene med sykepleier.
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7. HVORDAN UNNGÅ TILBAKEFALL ?
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Måneder etter røykestopp
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2. Lag røykeforbud i ditt eget hjem. Da blir det lettere både 
for deg og dine nærmeste å forbli røykfrie.  
3. Noe av det første du bør gjøre når du nå har sluttet å 
røyke, er å bli klar over i hvilke situasjoner fristelsen er 
størst. I mange situasjoner vil du føle røykesug. Hvis du 
får tankene over på noe annet varer røykesuget bare i ca. 
3-4 minutter. Gå igjennom denne listen og se hvilke 
situasjoner som passer best med dine røykevaner.
Jeg får ekstra lyst på røyk
når jeg begynner dagen.
etter at jeg har spist.
når jeg drikker kaffe.
når jeg drikker alkohol.
når jeg er sammen med andre på fest.
når jeg tar en pause.
når jeg er stresset eller har behov 
for å roe meg ned.
når jeg må vente på noe eller noen.
Tenk så igjennom hva du skal gjøre når røykesuget kommer.
Stikkordet er: Få tankene over på noe annet.
?
når jeg kjører bil.
når jeg snakker i telefonen.
når jeg kjeder meg.
når jeg synes jeg fortjener en 
belønning.
når jeg er stresset.
når jeg er engstelig.
når jeg er deprimert.
når jeg føler meg «likeglad».
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7.3   Noen andre tips:
• Flytt deg fysisk vekk fra den situasjonen du er i når 
røykesuget kommer.
Lag f.eks. en liste over alle ting som må gjøres i huset, i 
hagen, med bilen eller med en hobby. Når røykesuget 
kommer tar du fram listen, og går i gang med oppgavene.
• Ikke bli sittende når du har spist. Bryt opp og gjør noe annet.
• Unngå stressituasjoner de første ukene.
• Unngå alkohol de første vanskelige ukene. 
Motstandskraften svekkes når du drikker, og de fleste 
risikerer å sprekke
• Drikk mindre kaffe. Forbrenningen av kaffe (i leveren) 
settes kraftig ned når du slutter å røyke. Du kan få 
symptomer på koffein-forgiftning hvis du ikke reduserer 
inntaket. Disse symptomene er ofte helt like nikotinabsti-
nensen! Du bør redusere inntaket av kaffe/te med minst 50%.
• Fjern alle røykesaker og alt som kan minne om tobakk  
hjemme, i bilen og på jobben.
• Fortell familie, venner og kollegaer at du har sluttet. Da 
risikerer du ikke så lett å bli tilbudt en sigarett. Samtidig 
blir det vanskeligere å begynne igjen.
• Legg gjerne pengene til side som du før brukte på tobakk. 
Bestem deg for noe å bruke dem til den dagen du er 
ferdig med avvenningen (f.eks. etter 1 år). Det blir mye 
penger ! 
• Pass på vekten. De fleste legger på seg 2-3 kg i starten. 
Apetitten øker og forbrenningen nedsettes. Forsøk å 
spise sunt. Prøv å unngå småspising. Mosjon nedsetter 
røykesuget. Gå gjerne turer o.l. Det er fint for hjertet ditt 
uansett!
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8. HAR DU RØYKT UNDER 
INNLEGGELSEN ?
• Sett en sluttdato sammen med sykepleier innen 3-4 uker 
etter utskrivelsen.
• Trapp gradvis ned nikotinforbruket. Det er stor 
forskjell på å stupe fra 10-meteren og fra bassengkanten. 
Du skal ned på bassengkanten før du jumper uti. 
Bytt til tobakk med mindre nikotininnhold. De første 4-5 
dagene kan du ellers røyke som før. Antakeligvis røykte 
du noe mindre enn vanlig på sykehuset. Ikke røyk flere 
sigaretter enn da du var innlagt. Etter ca. en uke trapper 
du ned på antall sigaretter. Bestem deg på forhånd hvilke 
sigaretter du skal kutte ut. Det kan da være lurt å kutte ut 
«de beste» først. Det er de som er vanskeligst å være 
foruten, og det er lurt hvis de ikke står igjen til slutt.
• Samtidig kan du prøve  å vente 15 minutter hver gang du 
har lyst på røyk.
• Gjør klar det antallet sigaretter du skal røyke pr. dag, og 
legg disse i en egen eske.
• Lag «rene» røykesituasjoner. Dvs. du skal  ikke lese, se 
på TV, snakke i telefon, kjøre bil osv. når du røyker. Du 
skal heller ikke røyke sammen med andre. På denne 
måten vil du automatisk røyke mindre, og du gjør noe 
aktivt for å bryte din røykevane. 
Når sluttdatoen er der, kan du følge anbefalingene som under
punkt 7.
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9 TILBAKEFALL
Ikke se for mørkt på dette. Mange har flere tilbakefall før de
endelig blir røykfrie. Tilbakefall er en del av prosessen med å
bli røykfri ! Prøv å ta lærdom av det, og tenk igjennom hva
som gikk galt. 
• Hvor skjedde det, -i hvilken situasjon ?
• Hva fikk deg til å begynne igjen?
• Hvem fikk deg til å begynne igjen ?
• Hva kan jeg gjøre annerledes neste gang?
Avtal så en ny sluttdato sammen med sykepleier. Trapp grad-
vis ned nikotinforbruket og forsøk på nytt.
De største seire blir sjeldent vunnet etter det første slaget.
Johan Falkberget.
10 NIKOTINPREPARATER
15
Nikotinpreparater avgir nikotin til blodet, og demper derved
abstinensplager i forbindelse med røykeslutt. Preparatene får
du kjøpt uten resept på apotek.
Mange klarer å slutte uten bruk av nikotinpreparater. Hvis du
ikke har røykt under innleggelsen er du over den verste peri-
oden med fysiske abstinenssymptomer, og vil bare ha nytte
av nikotinpreparater hvis du får plager med situasjonsbeting-
et røykesug.   
Du må ALDRI røyke samtidig som du bruker nikotin-
preparater. Da kan du få for mye nikotin i blodet, og det 
kan være uheldig for hjertet.
Vi vil anbefale nikotinpreparater hvis du er mye plaget med
røykesug eller har mye av de fysiske abstinenssymptomene.
10.1    For deg med situasjonsbetinget røykesug
Nikotintyggegummi anbefales
Forsøk først med laveste styrke (Nicorette 2 mg eller
Nicotinell 2 mg). Ved manglende effekt kan du øke til høy-
este styrke (Nicorette 4 mg eller Nicotinell 4 mg). 
Ta en tyggegummi når du føler røykesug. Hvis du på forhånd
vet at røykesuget vil komme, bør du ta den noen minutter
før. Det tar 30 minutter før du får maksimalt nikotinnivå i
blodet. 
Slik skal de tygges
Tygg langsomt til smaken kjennes sterkt (10-15 ganger). La
deretter tyggegummien hvile i munnen i ca. 1 minutt eller til
smaken avtar. Tygg langsomt 10-15 ganger til, og la igjen
tyggegummien hvile før du fortsetter på samme måte. 
Svelg minst mulig under tyggingen (Nikotinen tas opp fra
slimhinnen i munnen).
Etter ca. 30 minutter er alt nikotinen tygget ut av tygge-
gummien.
Bruk ikke mer enn 8-12 tyggegummier pr. dag. Ta bare en
om gangen.
10.2    For deg med fysisk abstinens
Nikotinplaster anbefales.
Dette gir en jevn tilførsel av nikotin til kroppen. 
• Hvis du har sluttet å røyke under innleggelsen eller røyk-
er mindre enn 20 ferdigsigaretter daglig kan du  begynne
med middels styrke:
Nicorette 10 mg/16 t. eller Nicotinell 14mg/24 t.
Hvis du fremdeles har symptomer kan du øke til høyeste
styrke (se nedenfor).
Etter 2-3 uker kan du skifte til svakeste styrke :
Nicorette 5 mg/16 t. eller Nicotinell 7mg/24 t.
Etter ytterligere 2-3 uker kan du slutte med plaster. 
• Hvis du ikke har sluttet å røyke under innleggelsen og
røyker mere enn 20 ferdigsigaretter daglig eller røyker rulle-
tobakk :
Begynn med høyste styrke nikotinplaster:
Nicorette 15 mg/16 t. eller Nicotinell 21 mg/24 t.
Etter 2 uker skiftes til middels styrke. Etter ytterligere 2 uker
skiftes til laveste styrke, som du kan bruke i 1-2 uker.
Nicorette plaster tas av hver kveld, og det settes på et nytt
neste morgen. Nicotinell plaster skiftes hver morgen.
Plasteret settes på hårfri, tørr og ren hud. Det presses i 10-15
sekunder mot huden. Stedet hvor plasteret settes varierer fra
dag til dag for å unngå hudirritasjon. 
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- for you who really needs it 
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1. Dear,__________________ 
You have just suffered a heart attack, unstable angina or coronary bypass surgery. You may 
have found the disease dramatic, and you may think: 
• What about the future? 
• How will the rest of my life be? 
• What can I do myself, and what do I have to avoid? 
• What will my daily life be like after this? 
Very much science has been performed regarding heart diseases, and we know a lot about 
how to help you. All kinds of investigation, medication and treatment for your condition aim 
at avoiding another heart attack . Treatment has improved greatly during the last years. Still, 
many smokers experience the same as you. Heart disease is still a typical smoking-related 
disease. 
 But now to the positive part: You wish to stop smoking. Your increased motivation 
has emerged probably because you do not want to experience this one more time. Quitting 
smoking is the most important action to avoid another attack of heart disease. None of 
the medications or treatment modalities we have today are as effective as smoking cessation 
in order to prevent the condition you now have survived.  So, although today’s high-tech 
medicine is of great importance, we have to admit that what you can do by yourself is more 
important than what we can do for you. This does not mean that our high-tech medicine is 
ineffective. On the contrary, it is very effective. However, quitting smoking is twice as 
effective in preventing another heart attack! 
 Many find it difficult to stop smoking. That is why we want to help you. We have 
some knowledge about the problems of smoking cessation, and if we can give you some 
advice to stay free of smoking, we know that we have helped you in the best way. 
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We hope this booklet, and the help you receive from Sørlandet Hospital, can motivate you to 
stay free of smoking. 
Good luck! 
 
Sincerely, 
 
Tone Bæck, nurse. Finn Tore Gjestvang, Chief consultant, Dep. of 
heart diseases.  
 
Eva Borøy, nurse.    Petter Quist-Paulsen, physician. 
 
 
 
 
 
This booklet was written by: Tone Bæck, Frode Gallefoss, Finn Tore Gjestvang, Eva Borøy, 
and Petter Quist-Paulsen. 
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2. About the health effects of tobacco 
We know today that half of those who smoke dies many years ahead because of smoking. 
Smoking is the cause of many cancers, especially in the lung, oesophagus, stomach, kidney, 
and urinary bladder. But it also leads to blood vessel diseases like heart attack, angina, and 
stroke.  
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3. Smoking and heart disease 
Some of you my find the following hard to accept. But as health care providers we feel it is 
our duty to give you all the facts about the health hazard of continued smoking. Many people 
stay healthy for years despite smoking and may never develop smoking-related disease. 
Unfortunately, you have now got heart disease. This may support the fact that your heart does 
not tolerate smoking. 
Smoking leads to 
Occluded vessels to the heart muscle 
The vessels around the heart supplies blood to the heart muscle. Smoking increases the 
thickness of the vessel wall, and during several years of smoking the vessel becomes 
narrowed and regional blood flow decreases. This is called atherosclerosis. When the vessels 
narrows, angina subsequently develops, and when they occlude, a heart attack arises. 
 
 
 
                     A narrowed blood 
           vessel leads to 
           angina.       
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Sticky platelets 
The platelets accomplish blood coagulation, and the development of a blood clot. 
Immediately after smoking, the platelets become more sticky. They may then adhere to the 
diseased blood vessel wall and cause a blood clot. If this happens in the coronary arteries, a 
heart attack develops. 
 
 
 
 
An occluded vessel 
leads to a heart attack 
 
 
 
 
 
Heart rhythm disturbance 
Nicotine in the tobacco increases the pulse with about 10-15 beats per minute. Some 
medications prescribed after a heart attack works by slowing down the pulse. Therefore, 
smoking may outweigh the effect of these medications. Further, the nicotine may also lead to 
heart rhythm disturbances, some of which may be dangerous. 
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4. Some statistics to your advantage 
Many factors like high cholesterol level, high blood pressure, inheritance and smoking may 
contribute to the heart disease you now are suffering from. What’s important about smoking 
as a cause of heart disease, is that it can be totally removed! If you manage to quit smoking, 
your life expectancies will increase dramatically compared to continued smoking. Many 
investigations have shown that smoking cessation is very effective in patients with heart 
disease, and that the effect is evident shortly after cessation. If you manage to stay free of 
smoking your chance of dying because of heart disease is reduced by approximately 50% 
after one or two years of abstinence. None of the pharmaceuticals you receive are comparable 
to this effect. 
Risk of death 5 years after a heart attack 
 
 
Relative risk 
 
  
 
 
 
 
 
 
 
 
 
Stopped smoking 
Continued smoking 
This figure shows a 60% risk 
reduction for death five years 
after a heart attack in patients 
who managed to stop 
smoking compared to 
patients who continued to 
smoke 
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The longer you manage to stay free of smoking, the larger is the effect on mortality, as shown 
by this figure: 
 
 
This investigation found that 13 years after a heart attack or unstable angina 63% were still 
alive in the group that managed to quit smoking, compared to only 18% among those who 
continued smoking. 
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5. About nicotine dependence 
Nicotine causes dependence, and that is why many find it difficult to quit smoking. You may 
feel irritable, restless, or miserable after cessation because your body has got used to the 
nicotine, and reacts with abstinence when nicotine concentration declines. This is related to 
physical dependence. You may also long for the pleasant feeling the nicotine creates when it 
reaches the brain some seconds after inhalation, and this is related to psychological 
dependence. 
1. Physical abstinence 
Symptoms: 
Headache, tiredness, shivering, sleep disturbance, concentration impairment, dizziness, 
irritability, anxiety, depression. 
These symptoms are most severe the first 2-3 days, and then gradually declines over the next 
2-4 weeks. When you read this, you already have lived through the most troublesome physical 
abstinence. In other words, the most unpleasant period has already passed! What you now 
have to fight against is the psychical dependence. 
2. Psychological dependence 
For a long time, your brain will remember the pleasant feeling that may arise after inhalation. 
Therefore, you may often experience a desire for smoking in many situations, even long after 
the physical dependence has vanished. Some people struggle with this urge for several years 
after cessation. When this urge develops, you have to remember that it is only a momentary 
feeling, and that it will go away after a few minutes. 
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6. Have you stayed “smoke free” during hospitalisation? 
That is excellent, half of the job has already been done! Most of the abstinence has already 
passed. If you have not experienced physical abstinence during hospitalisation, you most 
probably never will suffer from this. Now, you can fully concentrate on relapse prevention.  
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7. How to prevent relapse? 
The most important: NEVER try “just one cigarette”. 
Studies have shown that if you smoke just one cigarette, the chance of relapse is large even 
after several years of abstinence. You have to think: “One time smoker, always smoker.” Only 
one cigarette at Christmas eve, New Years eve, or at your birthday may well start regular 
smoking again.  
 The following figure shows that relapse to smoking is rather infrequent after four 
months of abstinence:  
 
 
 
   The percentage  
   that remains 
  free of smoking 
  after a quit-attempt 
 
 
 
                                                  
 
If you manage to stay free of smoking the first 4-5 months, you probably will succeed! 
Some other important elements 
Several investigations on how to stop smoking have been performed. Maybe you will find 
some of the following elements helpful in staying free: 
Months after smoking cessation 
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1. If your spouse is smoking, it is difficult to succeed. Try to convince he/her to quit along 
with you. Your spouse is welcome to join the consultations with the nurse who is going to 
help you to stay free. 
2. Abandon smoking in your own house. Then it will be easier for both you and your family 
to stay free. 
3. You might find it wise to think through the situations when your  smoking urge is at its 
highest. If you manage to think of something else, or keep occupied with something else, 
the urge to smoking will disappear after 3-4 minutes. Others have found that resisting 
smoking may be difficult in the following situations. Maybe some of these situations also 
pose  problems for you: 
It is difficult to resist the urge to smoke 
when I start the day. when I drive a car. 
when I drink coffee. when I am bored. 
after eating. when I feel anxiety. 
when I talk in the phone. when I am depressed. 
when I drink an alcoholic beverage. when I don’t care about nothing. 
when I deserve an award. when I am stressed or want to calm down. 
when I am on a party. when I am waiting for someone or something.
when I am taking a break.   
 
What will you do when the urge arises in these situations? Most important is probably to 
move you mind and think of something else, and NEVER try ”just one cigarette”.  
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Some more advises 
• Remove yourself physically away from the place where the urge develops. You may want 
to make a list of things you have to do in the house, in the garden, or with a hobby. When 
the urge arises, go ahead with the tasks! 
• After eating a meal, go on and do something else in stead of stay seated. 
• Avoid stressing situations the first couple of weeks. 
• Avoid alcohol the first weeks. 
• Drink less coffee. Nicotine increase the metabolism of coffee when smoking. Therefore, 
symptoms of coffein intoxication, which may be very similar to nicotine withdrawal 
symptoms, may develop if you do not reduce the amount of coffee! 
• Remove all smoking-related advises in the house. 
• Tell your family and friends that you have stopped smoking. Then, they probably will not 
offer you a cigarette, and it may be easier to stay free. 
• You may want to put away the money you are saving by not smoking, and use them on 
something nice. It’s a lot of money! 
• Watch your weight. Many increases 2-3 kg in weight. Try nor to eat between meals. 
Exercise will help, and is good for your heart! 
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8. Have you smoked during the hospitalisation? 
• Set a quit-date together with the nurse within 3-4 weeks after discharge. 
• Gradually lower the number of cigarettes per day. You have nevertheless probably 
smoked a bit less than usual while hospitalised. Do not increase the amount to the 
previous level when you come home! After one week you should reduce the number of 
cigarettes per day. It is often wise to remove “the best ones” first (i.e. the cigarette after 
dinner). They are the most difficult to avoid, and should not be the last to go! 
• Try to wait for 15 minutes every time you want a cigarette. 
• Lay aside the cigarettes you are allowed to smoke in a day. 
• Develop “pure smoking situations”. In other words, you shall only smoke when smoking, 
and not read, watch television, talk in the phone etc. at the same time.  
• When you reach the quit-date, you are advised to follow the recommendations in chapter 
7. 
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9. Relapse 
Try not to be depressed about this. Most people that at last manage to quit smoking have 
relapsed several times. Relapsing is part of the process of quitting! Try to learn from it. What 
went wrong? 
• Where did it happen? 
• What got you started? 
• Who got you started? 
• What can I do better next time? 
Arrange a new quit-date with the nurse, start gradually reduction of the number of cigarettes 
per day, and have try again! 
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10. Nicotine replacements 
Nicotine replacements deliver nicotine to the blood, and thereby reduces the physical 
abstinence after smoking cessation. The products can be bought at pharmacies and in grocery 
stores without prescription from a doctor.  
 Many people manage to quit smoking without nicotine replacements. If you have 
stayed free of smoking while hospitalised, the period with a high level of physical abstinence 
has already passed, and you only need nicotine replacements when you experience situation-
related urge.  
 You should not smoke while using the replacements because of the risk of high level 
of nicotine concentration in the blood, which could be dangerous to your heart. 
 We recommend the use of replacements if you either have problems with physical 
abstinence or with situation-related urge. 
If you experience  situation-related urge 
Nicotine gum is recommended 
First you can try the gums with the lowest nicotine content (Nicorette 2 mg or Nicotinell 2 
mg). If this is ineffective, you may tray a gum containing 4 mg of nicotine. When the urge to 
smoke develop, you take a gum. If you in advance know that the urge will turn up, you should 
take a gum some minutes before the situation arises. It takes 30 minutes of chewing before the 
highest level of nicotine in the blood is reached. 
How to chew the gums 
Chew slowly until the taste becomes strong (10-15 times). Then put the gum aside in the 
mouth for approximately one minute, or until the taste disappear. Then repeat the process. The 
nicotine is released to the blood via the mucous membrane, and after about 30 minutes there 
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are no nicotine left in the gum. You should not use more than 8-12 gums per day, and only 
one at a time. 
For you with physical abstinence 
Nicotine patch is recommended 
A steady supply of nicotine to the blood is delivered by the nicotine patch.  
1. If you have stopped smoking while hospitalised, or if you are smoking less than 20 
cigarettes per day, you can  
• Start with a patch with medium concentration: Nicorette 10 mg/16 h or Nicotinell 14 
mg/24 h. 
• If you still have nicotine withdrawal symptoms, you can change to the patch with the 
highest concentration (see below). 
• After 2-3 weeks, change to the lowest concentration: Nicorette 5 mg/16 h or Nicotinell 
7 mg/24 h. 
• After another 2-3 weeks you can stop with the patches. 
2. If you have smoked during hospitalisation, and are smoking more than 20 cigarettes per 
day: 
• Start with the patch with the highest concentration: 
• Nicorette 15 mg/16 h or Nicotinell 21 mg/24 h. 
• After 2 weeks change to the medium strength, and after another 2 weeks to the lowest 
strength which you can use for 1-2 weeks. 
You have to take off the Nicorette patch every evening, and apply another one in the morning. 
The Nicotinell patch has to be exchanged every morning. The patches must be applied on dry 
and clean skin which is free of hair. You have to press it against the skin for 10-15 sec. To 
avoid skin-irritation you should vary the places for application. 
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Side effects 
To much nicotine: Pallor, sweating, increased salivation, nausea, diarrhoea, headache. 
Patches: Local skin irritation. 
Gums: Hiccup, irritation in the mouth and throat, abdominal pain. The gum may stick to, and 
injure tooth-prosthesis. 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
